Gresham Insurance Company Limited

Solvency and Financial Condition Report

Year ended 31 December 2022



Contents

А	Business and Performance	3
В	System of Governance	7
С	Risk Profile	14
D	Valuation for Solvency Purposes	20
E	Capital Management	28
F	Appendices	32
F.0 F.1	Cautionary Statement Public Disclosure Quantitative Reporting Templates	33 33
F.1.1 F.1.2.1 F.1.3.1 F.1.3.2 F.1.4 F.1.5 F.1.6 F.1.7 F.1.8	S.02.01 Balance Sheet S.05.01 Premium claims and expenses (by line of business) [life] S.12.01 Technical Provisions [life] S.17.01 Technical Provisions [non-life] S.19.01 Insurance claims [non-life] S.22.01 Impact of transitional measures S.23.01 Own Funds S.25.02 Solvency Capital Requirement S.28.01 Minimum Capital Requirement	34 36 39 41 43 44 45 46
F.2 F.3 F.4	Glossary of Abbreviations and Definitions Directors' Statement External Audit	48 49 50

Gresham Insurance Company Limited

Solvency and Financial Condition Report

2022

Summary

The purpose of the Solvency and Financial Condition Report (SFCR) is to provide information required by the Solvency II (SII) regulatory framework and in particular the capital position of Gresham Insurance Company Limited (the Company) at 31 December 2022.

The report sets out different aspects of the Company's business and performance, system of governance, risk profile, valuation methods used for solvency purposes and its capital management practices.

Business and Performance

The Company is a limited company registered in England and Wales and member of the Aviva plc group of companies. The Company transacts general insurance business in the United Kingdom through a business arrangement with Barclays Bank plc. The major class of business underwritten is personal lines home insurance. Whilst the Company only conducts non-life insurance activities, it also has life insurance obligations in relation to annuities stemming from non-life insurance contracts (through Periodical Payment Orders 'PPO').

The Company made an IFRS profit before tax of £3,128 thousand in the year ended 31 December 2022 (2021: £1,577 thousand). This comprised underwriting profit of £945 thousand (2021: loss £37 thousand), net investment expense of £60 thousand (2021: expense £735 thousand) and other income of £2,243 thousand (2021: other income of £2,349 thousand).

Gross written premium fell by 14% in the year (2021: fell by 5%) as a result of the highly competitive home insurance market. The majority of written premium is ceded to the Company's parent AIL, through a quota share reinsurance arrangement, with levies being excluded from this arrangement. Gross claims incurred of £55,255 thousand (2021: £39,245 thousand) increased due to due to adverse claims performance.

The Company's net investment expense for the year of £60 thousand (2021: expense £735 thousand) comprised interest receivable of £1,595 thousand (2021: receivable £968 thousand) and unrealised losses on the Company's holding of financial investments in Government Bonds and Collective Investment Undertakings of £1,654 thousand (2021: unrealised loss £1,704 thousand). The Company received non-insurance income such as legal expenses, sold as add-ons to existing policies of £2,243 thousand (2021: income £2,349 thousand).

The Board has not declared an interim dividend (2021: interim dividend of £4,700 thousand).. There have been no other significant business or other events during the year which have had a material effect on the Company.

Section A of this report sets out further details about the Company's key operations and financial performance over the year.

System of Governance

The Board's responsibilities include ensuring that an appropriate System of Governance is in place throughout the Company. To discharge this responsibility, the Board has established frameworks for risk management and internal control using a 'three lines of defence' model. However, the Board sets the Company's risk appetite itself. A strong system of governance throughout the Company aids effective decision-making and supports the achievement of the Company's objectives for the benefit of customers, shareholders and regulators. Key features of the Company's System of Governance are as follows:

The roles and responsibilities of the Board are well defined;

- The Company's Board has delegated responsibilities to management within the Aviva Group to assist in its oversight of risk management and the approach to internal controls;
- · The Company has implemented four key control functions Risk Management, Actuarial, Compliance and Internal Audit;
- The Company has in place a remuneration policy, skills requirements and procedures for assessing the fitness and propriety of senior management and key function holders;
- The Company's risk strategy, appetite and framework, its approach to its Own Risk and Solvency Assessment (ORSA), and its governance
 over the use of the standard formula are set out in its Risk Management Framework policy and its risk policies and business standards;
 and
- The Company's outsourcing strategy is supported by its Procurement and Outsourcing Business Standard.

There have been no other material changes in the Company's system of governance during the year.

Section B of this report provides further details of the Company's System of Governance.

Risk Profile

The Company's business is about protecting its customers from risk. As an insurer, the Company accepts the risks inherent to its core business line of non-life insurance.

The Company receives premiums which are invested in order to maximise risk-adjusted returns, so that the Company can fulfil its promises to customers while providing a return to its shareholders. In doing so, the Company has a preference for retaining those risks which it believes it is capable of managing to generate a return.

The types of risk to which the Company is exposed have not changed significantly over the year and remain credit, market, underwriting, liquidity and operational risks.

For those risk types managed through the holding of capital, the Company measures and monitors its risk profile on the basis of the Solvency Capital Requirement (SCR). Some categories of risk are not measured and managed solely by holding capital, principally liquidity risk, which is measured through both absolute level targets and bespoke liquidity coverage ratios.

Section C of this report further describes the risks to which the Company is exposed and how it measures, monitors, manages and mitigates these risks, including any changes in the year to the Company's risk exposures and specific risk mitigation actions taken.

Valuation for Solvency Purposes

Assets, technical provisions and other liabilities are valued in the Company's SII Balance Sheet according to the SII regulations. The basis of the SII valuation principle is the amount for which they could be exchanged, transferred or settled by knowledgeable and willing third parties in an arm's length transaction. The value of Technical Provisions under SII is equal to the sum of a Best Estimate Liability and a Risk Margin.

At 31 December 2022, the Company's excess of assets over liabilities was £16,178 thousand (2021:£12,950 thousand) on a SII basis which is £1,104 thousand (2021:£1,004 thousand) higher than the value under IFRS.

Section D of this report provides further description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset or liability class. In addition, it also provides an explanation of the material differences between the IFRS and SII bases of valuation.

Capital Management

The Company manages Own Funds in conjunction with solvency capital requirements. In the calculation of the SCR, the Company has chosen to implement the standard formula (SF). In managing capital, the Company seeks, on a consistent basis, to:

- · Match the profile of its assets and liabilities, taking into account the risks inherent in the business;
- Maintain sufficient, but not excessive, financial strength to support new business growth, and satisfy the requirements of the Company's regulators and other stakeholders, giving the Company's customers assurance of its financial strength;
- · Retain financial flexibility by maintaining strong liquidity; and
- Allocate capital rigorously to support value adding growth and repatriate excess capital where appropriate.

There have been no material changes to the objectives, policies or processes of the Company for managing its Own Funds during the year.

At 31 December 2022, the total eligible Own Funds to meet the SCR was £16,178 thousand (2021: £12,950 thousand) all of which was represented by unrestricted tier 1 capital. The Company's SCR, at 31 December 2022, was £4,816 thousand (2021:£3,536 thousand). The overall surplus position was £11,362 thousand (2021: £9,414 thousand) which translates to a regulatory cover ratio of 336% (2021: 366%).

Section E of this report further describes the objectives, policies and procedures employed by the Company for managing its Own Funds. The section also covers information on structure and quality of Own Funds and calculation of SCR, including information about the Company's use of SF.

Gresham Insurance Company Limited Solvency and Financial Condition Report 2022

A. Business and Performance

In this Chapter

- A.1 Business and Performance
- A.2 Underwriting Performance
- A.3 Investment Performance
- A.4 Performance of Other Activities
- A.5 Any Other Information

3

A. Business and Performance

The 'Business and Performance' section of the report sets out the Company's business structure, key operations, and financial performance over the reporting period.

A.1 Business

The Company is a limited company, registered in England and Wales, and is a member of the Aviva plc group of companies (the Group).

Qualifying holdings

The Company's shares and the associated voting rights are wholly owned by AIL, being a qualifying holding in the Company.

Supervisor

The Company is authorised by the Prudential Regulatory Authority (PRA). The Company and the Group are regulated by the PRA and the Financial Conduct Authority (FCA) in the UK. The PRA is part of the Bank of England. Contact details for the PRA are as follows:

Address Telephone number 20 Moorgate, London, EC2R 6DA +44 (0) 20 7601 4444

retephone numbe

External auditor


The PRA have issued the Company waiver to exempt the SFCR from the external audit requirements in the PRA handbook. Consequently, all qualitative and quantitative disclosure in this document is unaudited.

Financial statements

The Company's financial statements are available from the Company Secretary, Aviva Company Secretarial Services Limited, St Helen's, Undershaft, London, EC3P 3DQ.

A.1.1 Organisation

The following chart shows, in simplified form, the Company's position within the structure of the Group as at 31 December 2022:



* Incorporated in the United Kingdom

Gresham Insurance Company Limited is a subsidiary of Aviva Insurance Limited, which is registered in Scotland. Aviva plc is the ultimate controlling parent entity registered in England.

A.1.2 Business operations and events occurring in the year

Business operations

The only material SII line of business underwritten by the Company is Fire and Other Damage to Property. The Company underwrites its business in the UK, as presented in QRT S.05.01 (Appendix F.1).

Whilst the Company only conducts non-life insurance activities, it does have life insurance obligations in relation to annuities stemming from non-life insurance contracts (PPO).

Significant business and other events

The Company underwrites personal household business, and the 100% quota share reinsurance arrangement with its parent company, Aviva Insurance Limited.

The Company is taking a cautious approach on capital given the uncertain economic outlook. The Company's balance sheet exposure and solvency position has been continually reviewed during the year and actions taken to protect the solvency position and further reduce the sensitivity to economic shocks. The Company's Solvency II capital surplus of £16,178 thousand (2021: £12,950 thousand) is a key metric for the Company and remains strong.

During 2022 global markets have experienced significant turmoil. Despite this, the impact on the Company is not considered to be significant given that the company underwrites personal household business, and the 100% quota share reinsurance arrangement with its parent company, Aviva Insurance Limited ("AIL").

A.2 Underwriting Performance

A.2.1 Measurement of underwriting performance

The Company uses the underwriting result to measure its underwriting performance. Underwriting result is a non-GAAP financial performance measure, calculated on an IFRS basis. It excludes certain items to enhance comparability and understanding of underwriting performance by highlighting net income attributable to on-going underwriting operations. Examples of items excluded from underwriting result are investment return, economic assumption changes, and non-insurance income. The items excluded from underwriting result, which comprise the Company's investment performance and its performance of other activities, are detailed in sections A.3 and A.4 respectively.

A.2.2 Underwriting performance during the year

The Company made a profit before tax of £3,128 thousand for the year ended 31 December 2022 (2021: £1,577 thousand). This comprises an underwriting profit of £945 thousand (2021: loss £37 thousand), net investment expense of £60 thousand (2021: expense £735 thousand) and income from other activities of £2,243 thousand (2021: income £2,349 thousand), as shown in the table below

	£000s	£000s
Year ended 31 December	2022	2021
Profit for the year before tax	3,128	1,577
Less: Net investment income (see A.3)	60	735
Performance of other activities (see A.4)	(2,243)	(2,349)
Underwriting profit	945	(37)

Personal household business remains highly competitive and average premiums are lower following the impact of FCA pricing practices which came into force on 1 January 2022.

A.2.3 Solvency II lines of business

A summary of the information provided in the premium, claims and expenses QRT S.05.01, analysed by SII lines of business, is provided in the table below. The net result of £3,128 thousand (2021: £1,577 thousand) comprises the underwriting result of profit of £945 thousand (2021: loss £37 thousand) and the profit from other activities of £2,183 thousand (2021: profit £1,614 thousand).

	Fire and other		
	damage to	Other SII lines of	
£000s	property insurance	business	Total
Year ended 31 December 2022			
Gross written premium	98,769	3,055	101,824
Net earned premium	4,147	128	4,275
Gross claims incurred	(55,842)	587	(55,255)
Net claims incurred	1,144	(553)	591
Net expenses incurred	(1,725)	(53)	(1,778)
Total expenses			(1,778)
Year ended 31 December 2021			
Gross written premium	114,795	3,550	118,345
Net earned premium	5,543	171	5,714
Gross claims incurred	(37,235)	(2,010)	(39,245)
Net claims incurred	730	(927)	(197)
Net expenses incurred	(3,268)	(101)	(3,369)
Total expenses			(3,369)

The Company's gross written premium, which is underwritten in the UK, decreased by 14% (2021: decreased by 5%) as a result of the highly competitive home insurance market. The majority of written premium is ceded to the Company's parent AIL, through a quota share reinsurance arrangement, with levies being excluded from this arrangement.

Gross claims incurred of £55,255 thousand (2021: £39,245 thousand) increased due to adverse claims performance. Net claims incurred were positive £591 thousand (2021: negative £197 thousand) reflecting the reinsurance arrangement with AIL.

Net expenses incurred of £1,778 thousand (2021: £3,369 thousand) as a result of reduced business levels and include non-insurance income of £2,243 thousand (2021:£2,349 thousand).

Business and
SummarySystem of
PerformanceRisk
GovernanceValuation for
ProfileCapital
Solvency PurposesOther
ManagementInformation

A.3 Investment Performance

A.3.1 Measurement of investment performance

The Company's net investment expense for the year of £60 thousand (2021: expense of £735 thousand) comprised interest receivable of £1,595 thousand (2020: receivable £968 thousand) and unrealised loss on the Company's holding of financial investments in Government Bonds and Collective Investment Undertakings of £1,654 thousand (2020: loss £1,704 thousand). Net investment expense is stated after the deduction of immaterial investment expenses.

A.4 Performance of Other Activities

A.4.1 Other income and expense

As described in section A.2.1, performance of other activities comprises those items of other income and expense, other than net investment return, excluded from underwriting result. The Company made an IFRS profit before tax of £3,128 thousand in the year ended 31 December 2022 (2021: £1,577 thousand) of which £2,183 thousand (2021: £1,614 thousand) arose from its performance of other activities during the year. The material component of the Company's other activities is its non-insurance income of £2,243 thousand (2021: income £2,349 thousand). Non-insurance income arises from items, such as legal expenses, sold as add-ons to existing policies; this income has fallen during the year in line with premium.

A.5 Any Other Information

During January 2023, the Company has entered into a contractual agreement with its distribution partner Barclays Bank UK plc that will result in the Company terminating the current business arrangement on a target date in the third quarter of 2023 and acquiring renewal rights to in-force UK household insurance policies in return for an upfront payment to the distribution partner later in 2023. This payment, which will be determined with reference to the number of in force policies at that date, will be funded via capital injection from the parent. Brand migration of these policies from Barclays to Aviva will happen on the acquisition date, with no further new business acquisition into Gresham. The principal activity of the Company going forward will therefore be to administer and manage the in-force UK household insurance policies.

There is no other material information to report regarding the Company's Business and Performance.

Gresham Insurance Company Limited

Solvency and Financial Condition Report

2022

Summary

B. System of Governance

In this Chapter

- B.1 General Information on the System of Governance
- B.2 Fit and Proper Policy
- B.3 Risk Management System including the Own Risk and Solvency Assessment
- Internal Control System B.4
- B.5 Internal Audit Function
- Actuarial Function B.6
- B.7 Outsourcing
- Any Other Information B.8

B. System of Governance

This section of the report sets out information regarding the 'System of Governance' in place within the Company.

Details of the structure of the undertaking's 'administrative, management or supervisory body' (defined as the Board) are provided. The roles, responsibilities and governance of key functions (defined as the Risk, Compliance, Internal Audit and Actuarial Functions) are also provided. Other components of the System of Governance are also outlined, including the risk management system and internal control system implemented across the business.

B.1 General Information on the System of Governance

B.1.1 Board structure

The Company's Board is responsible for promoting the long-term success of the Company and for setting its strategy. It sets the Company's risk appetites and satisfies itself that financial controls and risk management systems are robust. A strong system of governance throughout the Company aids effective decision-making and supports the achievement of the Company's objectives for the benefit of policyholders and the shareholder.

The duties of the Company's Board are set out in its terms of reference. The terms of reference lists both those items that are specifically reserved for decision by the Board and those matters that must be reported to the Board. Until the 12 December 2022, the Company's Board was composed of senior management from within the Group and a Director nominated by Barclays Plc. The Barclays' director resigned on 12 December 2022 ahead of the execution of the contracts regarding the purchase of the Barclays Home portfolio by the Company, which was finalised on 20 January 2023. Since, 1 January 2023, the Company's Board is composed solely of senior management from Aviva

The Company's Board has delegated responsibilities to management within the parent Company (AIL) to assist in its oversight of risk management and the approach to internal controls.

The 'three lines of defence model', and roles and responsibilities of key functions

Aviva staff acting on behalf of the Company are involved in the management and mitigation of risk, with the RMF embedded in the day-to-day management and decision making processes. The three lines of defence model is adopted by the Company and across Aviva Plc (as required by the RMF policy). Further details are below:

The first line (The Business)

Accountable for the management of all risks relevant to the business of the Company. The Chief Executive Officer (CEO) is responsible for the implementation of the Company's strategies, plans and policies, the monitoring of operational and financial performance, the assessment and control of financial, business and operational risks and the maintenance and ongoing development of a robust control framework and environment in their areas of responsibility.

The second line (Risk Function)

- Accountable for providing independent objective quantitative and qualitative challenge and oversight and challenge of the identification, measurement, management, monitoring and reporting of material risks and for developing the RMF. Within the Risk Function the;
- Actuarial Function is accountable for actuarial methodology, and reporting to the relevant governing body on the adequacy of reserves and capital requirements, as well as on underwriting and reinsurance arrangements; and
- Compliance Function supports and advises the business on the identification, measurement and management of its regulatory and conduct risks and is accountable for monitoring and reporting on the Company's compliance risk profile.

The third line (Internal Audit)

The Internal Audit Function provides independent and objective assessment on the robustness of the RMF and the appropriateness and effectiveness of internal control to the Board.

Sections B.3.2, B.4.2, B.5 and B.6 detail the roles, responsibilities, authority, resources, independence and reporting lines of the Risk Management, Compliance, Internal Audit and Actuarial Functions respectively, and how their independence is ensured.

B.1.2 Material changes in the system of governance

As a consequence of the successful purchase of the Home portfolio from Barclays, the composition of the Board changed on 12 December 2022 following the resignation of the Director nominated by Barclays Plc. Going forward, the Company's Board will be solely composed of senior management from Aviva. There have been no other material changes in the system of governance during the year. The nature of Gresham's business and responsibilities are expected to change in Q3 2023 as a result of the successful purchase of the Barclays Home portfolio and both the parent company (AIL) and Gresham have put in place an internal Framework Service Agreement (FSA) to implement required changes to governance and oversight, and formalise the roles and responsibilities between the two entities. At various during 2022, AIL invoked crisis management procedures to manage effectiveness of its response to heightened economic uncertainty (including Gresham within these, as appropriate).

B.1.3 Adequacy of the Company's system of governance

An assessment of the effectiveness of the Company's governance, internal control and risk management systems was conducted at the end of 2022, including an attestation by the parent company's CEO. Key operational risks and any control weaknesses or non-compliance with the Company's risk policies and business standards or local delegations of authority are highlighted as part of this process. Significant progress has continued to be made with enhancing the Company's management of operational risk in 2022. This will remain a key focus in 2023, along with ongoing work in areas of regulatory focus. The parent company Chief Risk Officer (CRO) provided an independent opinion

on the parent company CEO's attestation which confirms accuracy of the CEO's declaration and noted no additional qualifications or weaknesses.

B.1.4 Remuneration policy.

All staff are employed by a fellow subsidiary of Aviva plc, Aviva Employment Services Limited, and a recharge is made to the Company. All Aviva staff acting on behalf of the Company are subject to the Group's remuneration policy, which is designed to incentivise and reward employees for achieving business goals in a manner that is consistent with the Group's strategy, business plans, values and behaviours, sound and effective risk management and good governance.

The directors of the Company receive no remuneration from the Company.

The director appointed by Barclays plc is remunerated in line with practices within Barclays plc.

Pension and early retirement schemes

There were no enhanced pension arrangements or early retirement schemes for members of the Board or key function holders in place during 2022.

B.1.5 Material transactions with the shareholder, persons with significant influence on the Company and members of the Board

The Company has a quota share reinsurance arrangement with AIL, with effect from 1 January 2006. The key terms of the agreement remain: a 100% cession rate on premiums, claims costs and underwriting expense costs is applied in respect of the underwriting year; and a requirement for the Company to retain a percentage in relation to levies.

The key management of the Company are considered to be the statutory directors. Note 4 to the financial statements gives details of their remuneration.

B.2 Fit and Proper Policy

B.2.1 Requirements for the persons who run the Company or who are other key function holders

For persons responsible for running the undertaking or responsible for key functions and assessment of fitness and propriety must consider their allocated responsibilities and skill and experience across the following areas:

- Insurance and financial markets:
- Business strategy and business models;
- System of governance;
- · Financial and actuarial analysis;
- · Regulatory framework and requirements; and
- Skills relevant to that role

The Company's requirements in respect of skills, knowledge and expertise for key function holders are set following engagement with both internal and external subject matter experts in each specialism. These requirements and qualifications are captured within individual role descriptions for each key function role.

B.2.2 Process assessing fitness and propriety

The Company has implemented processes to ensure that individuals employed within it, or acting on its behalf, are both fit and proper in line with the PRA and FCA Fit and Proper requirements for individuals subject to the Senior Managers and Certification Regime (SMCR). This means that, as part of recruitment and employee screening, an individual's career history will be assessed and validated to establish whether an individual's skills and knowledge are appropriately matched to the role. It also means that checks are in place to ensure that an individual is honest, of good reputation, has integrity and is financially sound.

The governance over the fitness and propriety of individuals includes recruitment, performance management and training. However, to ensure that the Company protects itself against employing individuals who potentially could threaten its customers, properties, facilities or reputation, the majority of its fitness and propriety processes take place at recruitment and more specifically at pre-employment screening. A minimum set of basic screening requirements has been agreed and implemented. Additional enhanced screening requirements are applied for individuals who are approved or certified under the SMCR and the fitness and propriety of these individuals is assessed annually. Individuals approved or certified under the SMCR are required to re-confirm annually their compliance with fitness and propriety requirements.

B.3 Risk Management System including the Own Risk and Solvency Assessment B.3.1 Risk Management Framework

The Company's RMF has a key role in supporting the business to deliver its purpose for our customers, our people and our shareholder, helping the business discover, predict, understand and manage our risks, thereby maintaining a safe risk environment. The RMF is at the heart of every business decision and is key to ensuring a robust control environment. The RMF comprises the systems of governance, risk management processes and Risk Appetite Framework (RAF) and is owned by the Company's Board. It establishes the principles and fundamental statements by which the Company Identifies, Measures, Manages, Monitors and Reports risk (IMMMR).

The Company's RAF outlines the risks that the Company selects and manages in pursuit of return, the risks the Company accepts and retains up to a moderate level of and the risks the Company actively avoids or takes action to mitigate as far as practical. It comprises:

- Risk preferences: which are qualitative statements that express where the business prefers to take risk (or else accept or avoid) and why, applied to individual key risks types (e.g. GI Reserving and Inflation).

- Risk appetites: which include overarching statements that express the level of risk the business is willing to accept. The Company
 has risk appetites for Solvency, Liquidity, Operational, Climate and Conduct risk. Risk appetites are reviewed and approved by the
 Board and monitored by the AlL relevant management committees.
- Risk limits: quantify more granular limits for specific defined risk exposure (e.g. maximum credit exposure limits to particular counterparties).

To promote a consistent and rigorous approach to risk management the Company has adopted a number of risk policies and business standards which set out the risk strategy and, appetite for risk and the expectations in respect of the management of risk. Compliance with these policies and standards is confirmed annually.

Risk management processes help the business discover, predict, understand and manage our risks, thereby maintaining a safe risk environment and enabling dynamic risk-based decision making. A variety of tools and processes are available to support risk identification. Top-Down Risk Assessment (TDRA) is carried out by the Risk Management Function and identifies key organisational current and emerging risks. Bottom up risk assessment focuses on risks more granular which are connected to our operational processes, managed through Risk and Control Self-Assessment (RCSA) process which is run by the first line, with challenge by the Risk Function. It focuses on operational risks, which are recorded on iCare, the Company's risk management system. These risk assessment processes are run separately but are complementary. They are used to generate risk reports which are shared with the Board.

Risk models are an important tool in the measurement of risks and are used to support the monitoring and reporting of the risk profile and in the consideration of the risk management actions available. A range of stress (where one risk factor is assumed to vary) and scenario (where combinations of risk factors are assumed to vary) tests are undertaken to evaluate their impact on the business and the management actions available to respond to the conditions envisaged.

The Risk Management Function is accountable for quantitative and qualitative oversight and challenge of the IMMMR process and for developing the RMF. Internal Audit provides an independent assessment of the risk framework and internal control processes.

The Board is responsible for setting the Company's risk preferences, risk appetites, and monitoring the establishment and operation of prudent and effective controls in order to assess and manage the risks associated with the Company's operations. Risk appetites are set for solvency, liquidity and operational risk and from 1 January 2022, have been set for climate and conduct risks.

The Company's position against its risk appetites is monitored and reported to the Board on a regular basis. Long-term sustainability depends upon the protection of franchise value and good customer relationships. As such, the Company has no appetite for risk of poor customer outcomes, market abuse or activities which impact market stability, integrity or fair competition, and takes all reasonable steps to comply with all conduct regulations and deliver good customer outcomes.

B.3.2 Risk Function

The Risk Function (Risk Management, Actuarial, Conduct and Compliance) is responsible for the design and implementation of the RMF. The Risk Function reports to the Company's Board on material risks, together with any other specific areas of risk requested by the Board, and assists the Board and management in the effective operation of the RMF including, amongst other things, the provision of specialist analysis and quality reviews, an aggregated view of the risk profile, and an assessment of the key risks associated with the business's strategy, and other key decisions.

The Risk Management Function has authority to review all areas of the Company and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work. The Board receives annual report and periodic verbal updates from the CRO covering material risks and concerns. The CRO has direct management accountability for the Risk Function and is responsible for prudential regulatory risk management.

Prudential risk management activities performed by the Risk Function include:

- Setting the prudential regulatory risk policy framework;
- Providing advice, support, guidance and challenge on prudential regulatory risk;
- Monitoring prudential regulatory developments; and
- · Managing prudential regulatory engagement.

B.3.3 Own Risk and Solvency Assessment (ORSA)

The ORSA is the entirely of the processes and procedures employed to identify, assess, monitor, manage and report the short-term and long-term risks the Company faces or may face to determine the own funds necessary to ensure that its overall solvency needs are met at all times, and determine sufficiency of resources necessary to ensure its long-term viability.

The ORSA reilies on the effective embedding of a number of elements of the RMF. The outcomes of the ORSA processes provide the Company's Board and management with a forward-looking assessment over the Plan horizon of all material risks and the extent to which they are covered by capital or addressed by risk mitigation techniques and capital requirements projections (including under stressed and reverse stress scenarios).

The parent company CEO and his direct reports are responsible for the majority of the underlying ORSA processes set out above. The Risk Function is responsible for the design of the RMF, including the ORSA Policy and annual ORSA reporting.

Review and approval

The Board oversees the ORSA processes and annually approves the ORSA policy. The results of the Company's ORSA processes are also considered by the Board when reviewing the Company's strategy and plans.

The annual ORSA report brings together and summarises in a single report a high-level description of the key components of ORSA, together with key developments and outcomes during the year.

The ORSA report is produced and approved by the Board annually, or in the event that material external events or management decisions amy require an update to the most recently prepared ORSA process outputs, depending upon their significance, to ensure that the Board's view on the Gresham's earnings, capital, liquidity, strategy and risk and control remain up-to-date. Accordingly, the occurrence of any or all of the following events are indicators of the need to consider whether an out-of- 'ad hoc' ORSA Report may be required:

- A material impact on Own Funds or diversified SCR
- The invocation of the parent company's Crisis Action Leadership Team (CALT), where the impacts materially pertain to Gresham; and/or
- Any potentially material change to Gresham's risk profile.

The annual report is submitted to the Board, and subject to their approval shared with the PRA.

Economic capital (as a risk-based capital measure) is embedded in the Company's RMF and is used as a key input to a wide range of business and strategic decisions. The framework, supported by risk policies and business standards, sets out the areas where economic capital management information must be used as part of decision-making and risk management processes. This ensures that requirements to use economic capital are embedded within the relevant processes including, but not limited to, strategy and planning. Economic capital is calculated using the SF calculation, the appropriateness of which is reviewed annually and reported to the Board.

B.4 Internal Control System

B.4.1 System of Internal Control

The Company's principles for ensuring effective internal control are set out in Risk Policies and Business Standards that set the global objectives and global controls to be applied across the Aviva Group, as well as the RMF and, in particular, the Operational Risk and Control Management (ORCM) Framework. These core risk documents set out mandatory business requirements as these relate to risk management and key controls. Compliance is attested in the annual CEO attestation completed by the parent compnay. Key attributes of the internal control environment include:

- An appropriate "tone from the top". This supports the effective management of exposures, adequate resourcing, effective communication, malpractice reporting, a business ethics code that is annually signed up to by all Aviva employees acting on behalf of the Company, and a commitment to integrity, ethical behaviour and compliance;
- A clear organisational structure that supports the system of internal control and includes the effective operation of an adequately
 resourced three lines of defence model, appropriate and proportionate segregation of duties, a clear system of delegated authorities,
 clearly defined roles and responsibilities for staff, and the consideration of risk management and control responsibilities when setting
 objectives for, and reviewing the performance of, all staff;
- Implementation of risk policies and business standards, and consistent IMMMR of all risks;
- A common system of record for operational risk reporting (iCARE) with standardised reporting;
- · Effective controls for each of its core risks which align to key business processes, and are regularly monitored and reported on; and
- A risk oversight process that provides adequate challenge to the completeness and openness of internal control and risk assessment of the Company's most material risks.

B.4.2 Compliance Function

The primary purpose of the Compliance Function is to assess and manage exposure to conduct regulatory risk. The Compliance Function is an integral part of the RMF and constitutes a key part of the Company's corporate governance, including relationships with the FCA and other regulatory bodies. The function is a critical contributor to the safe and sound operation of the Company and underpins the achievement of its strategy and business goals. The Compliance Function is led by the Chief Conduct and Compliance Officer (CCCO). The key processes that comprise the Company's compliance activity are:

- Setting the conduct policy framework;
- Providing advice, support, guidance and challenge on conduct risk;
- Monitoring conduct regulatory developments; and
- Managing conduct regulatory engagement.

Those responsible for carrying out compliance activities have authority to review all areas of the Company and have full, free and unrestricted access to all activities, records, property and personnel necessary to carry out their role, where appropriate.

The General Counsel is responsible for monitoring of legal developments.

B.5 Internal Audit Function

The Company's Internal Audit Function is led by the Internal Audit Director who reports directly to the Group Chief Audit Officer and to the Chairman of the parent company's Audit Committee.

The Internal Audit Function provides regular reports to the Company's Board on the robustness of the Company's RMF and the appropriateness and effectiveness of the system of internal control. In doing this it considers the adequacy of the Company's system of internal control to manage its business risk and to safeguard its assets and resources. It also considers the effectiveness of any actions put in place by management to address any deficiencies that might exist in the system of internal control.

Independence and objectivity

The Internal Audit Function maintains its independence and objectivity by reporting directly to the Group Chief Audit Officer and the Chairman of the parent company's Audit Committee. The parent company's Audit Committee has a duty to recommend the appointment or dismissal of the Chief Audit Officer to the parent company Board and to participate, jointly with the Group Chief Audit Officer or designee, in the determination of the objectives of the Chief Audit Officer and the evaluation of his levels of achievement, including consultation with the CEO.

The Chief Audit Officer proposes a budget which ensures that Internal Audit has sufficient skills and resources to discharge its responsibilities. Internal Audit is authorised to review all areas of the Company and has full, free, and unrestricted access to all activities, records, property, and personnel necessary to complete their work.

Internal Audit Function staff have no direct responsibility for any operational activities. There is a formal policy of rotating staff to ensure that independence is maintained. There is also a restriction on the audits that staff who have previously worked elsewhere in the Company can perform. The Internal Audit Function cannot perform any projects for management that will threaten its actual or perceived independence and objectivity.

An annual declaration of independence is signed by all members of the Internal Audit Function's staff.

B.6 Actuarial Function

The Actuarial Function is accountable for actuarial methodologies and calibrations, plus the resultant Best Estimate Liabilities and capital requirements. The Actuarial Function produces an annual report to the Board providing all of the information necessary for the Company's Board to form their own opinion on the adequacy of Technical Provisions and on the Company's underwriting and reinsurance arrangements.

The independence of the Actuarial Function is derived through its membership of the wider Risk Function. The Actuarial Function is led by the parent company Chief Actuary, who reports to the parent company CFO. Persons employed in certain specific roles within the Actuarial Function are subject to the Fit and Proper policy requirements to ensure they have the requisite skills and knowledge to complete their responsibilities. (Fit and Proper requirements are considered in section B.2.)

The Actuarial Function has the authority to review all areas of the Company and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work.

B.7 Outsourcing

Policy

The Aviva Procurement and Outsourcing Business Standard contains information on the Company's outsourcing policy, setting out the relevant responsibilities, objectives, process, and monitoring arrangements to be applied in cases of outsourcing, all of which shall be consistent with the overall strategy. The Business Standard applies equally to any externally or internally (intra-group) outsourced activity and is benchmarked against relevant regulatory expectations. The objective of this Business Standard is to ensure that adequate governance, minimum control objectives and controls for supplier-related activities are followed by all Aviva businesses, so that supply risk is managed effectively. This includes the need to ensure that, customers are being treated fairly, their best interests are protected and that the risk of potential financial, operational, contractual, and brand damage caused by inadequate management is mitigated. The standard requires a global Outsourcing Landscape document to be produced bi-annually which captures details of all Material outsourced operational functions and activities.

The Business Standard applied to all staff involved in suppler related activities. It provides clarity to businesses on the definition of outsourcing, including where activity is delegated to an intermediary, and whether a function or activity outsourced is assessed as Material.

The objectives and controls in the Business Standard cover the following areas:

- Supply governance: business oversight of operational performance for sourcing and supply management activities;
- Sourcing: how a service provider of suitable quality is selected; and
- Supplier management: risk-based approach to management of supply contracts.

Material outsourcing will attract the highest level of rigour, including any required regulatory notification, performance and relationship reviews, regulatory compliance reviews, operational resilience reviews, and risk and control assessments. The standard and the associated controls have been updated as appropriate to align to the PRA Regulations for Outsourcing and Third-Party Risk Management (PRASS2/21) from January 2022.

Material outsourced functions and activities

The Company receives a wide range of services from within the Group. Various claims handling and fulfilment activities, including loss adjusting and property repairs are outsourced to companies outside the Group.

Jurisdiction of service providers

Services provided from within the Group and claims handling and fulfilment activities are carried out in the UK and Spain with some support functions being carried out in India.

B.8 Any Other Information

With effect from the 1 January 2023, the Actuarial Function has transferred from the Risk Function to the Finance (1st line) Function. The Chief Actuary and Actuarial Function will retain independence as a Solvency II key (control) Function and will be supported in this both by

the Chief Actuary retaining direct access to AIL Board Committees / Board and through dotted-line reporting into the CRO. The Chief Actuary will continue to hold SMF20 regulated accountabilities. Oversight of actuarial and reserving risks and accountabilities for the Standard Formula will remain aligned to the Risk Function

In addition, as a consequence of Aviva's successful bid to purchase the Home portfolio from Barclays, the composition of the Company's Board changed on 12 December 2022 following the resignation of the Director nominated by Barclays Plc. Since 1 January 2023, the Company's Board is composed of senior management from Aviva. As at the formal date of the Home portfolio transferring from Barclays, in Q3 2023, any necessary changes to the Company's operating model will be implemented, including establishment of an internal Framework Services Agreement between the Company and its parent company, to formalise the roles and responsibilities between the two entities and implement required changes to governance and oversight.

Gresham Insurance Company Limited Solvency and Financial Condition Report 2022

C. Risk Profile

In this Chapter

Summary

- C.1 Underwriting Risk
- C.2 Market Risk
- C.3 Credit Risk
- C.4 Liquidity Risk
- C.5 Operational Risk
- C.6 Other Material Risks
- C.7 Any Other Information

14

C. Risk Profile

This chapter provides information on the Company's Risk Profile.

C.1 Underwriting Risk

C.1.1 Exposure

The Company's exposure to non-life underwriting risk arises from:

- Inadequate claims reserving assumptions;
- · Unforeseen fluctuations in the timing, frequency and severity of claims and claim settlements relative to expectations;
- Unexpected claims arising from a single source;
- Inaccurate pricing of risks or inappropriate underwriting of risks when underwritten; and
- Inadequate reinsurance protection or other risk transfer techniques.

The Company underwrites household insurance, transacted though a business arrangement with Barclays Bank plc. There are also some outstanding reserves in respect of motor business that was underwritten historically.

The Company has a quota share arrangement with its parent company, AIL, with effect from 1 January 2006. The majority of written premium is ceded to AIL, although an amount of premium is excluded from this arrangement to meet the cost of levies. The Company is also a named party to Group wide external catastrophe reinsurance arrangements and participates in the Flood Re reinsurance programmes which is backed by the UK Government.

There were no material changes to the Company's underwriting risk profile over the year to 31 December 2022.

The Company's overall exposure to underwriting risk is measured using the SCR. QRT S.25.01 (Appendix F.1.7) shows that the Company's undiversified SCR for underwriting risk is immaterial (2021: immaterial). Underwriting risk is also measured and monitored in terms of best estimate liabilities, total sum insured and estimated maximum loss. Estimated maximum loss is an estimation of the maximum loss that could be reasonably sustained as a result of a single incident considered to be within the realms of probability.

Inflationary pressures and supply chain disruption are an on-going key risk for achieving profit plans and a risk to solvency and liquidity positions. Forward looking estimates of claims inflation are uncertain and are driven by many factors, including current global events. The Company does not have material underwriting exposure to Russia and the Ukraine, and does not conduct operations in the affected region. The conflict in Ukraine and ongoing disruption to global supply chains has resulted in heightened claims inflation during 2022 which is expected to persist into 2023 and has increased the uncertainty associated with the cost of settling general insurance claims. While the impacts of heightened claims inflation are being mitigated via new business pricing actions, our ability to price for inflation is dependent on market, competitor and customer behaviour. The time lag between premium earning and claims emergence means that some adverse impact on profitability were observed in 2022.

The removal of the majority of government restrictions related to COVID-19 has led to claims frequency increasing to and stabilising at more normal levels.

There has been no material change to the measures used to assess underwriting risk during the reporting period.

C.1.2 Risk concentration

The Company's general insurance business is UK domiciled, and managed and priced in the UK. Its most concentrated non-life underwriting peril is North European Windstorm. The business written is sold exclusively via Barclays Insurance Services Company Limited.

C.1.3 Risk mitigation

The Company manages its exposure to general insurance risk through the application of control frameworks that include:

- Claims reserving that is undertaken by local actuaries and is also subject to periodic external review;
- Extensive use of data, financial models and analysis to improve pricing and risk selection;
- Underwriting limits linked to delegations of authority that govern underwriting decisions;
- · Product development in a management framework that ensures products and propositions meet customer needs;
- · Product limits and exclusions; and
- Governance of outsourced functions writing products on behalf of the Company.

The primary technique used to mitigate underwriting risk is reinsurance as described in section C1.1.

The management of insurance risk is overseen by the Board.

C.1.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.1.5 Special purpose vehicles

The Company has not transferred underwriting risk to special purpose vehicles, as defined by the SII Directive.

C.2 Market Risk

C.2.1 Exposure

The Company's exposure to market risk arises from the risk of adverse financial impact resulting directly or indirectly from fluctuations in interest rates and inflation. Market risk arises due to fluctuations in both the value of liabilities and the value of assets held.

Given the reinsurance the Company has in place as outlined in section C1.1, the Company is primarily exposed to fluctuations in interest rates affecting the value of its UK Government Bonds albeit this risk is currently modest given short duration of bond holdings. There is no exposure to foreign currency exchange rates.

There has been no material change in the Company's overall market risk exposure during the period.

The Company's overall exposure to market risk is measured using the SCR. QRT S.25.01 (Appendix F.1.7) shows that the Company's undiversified SCR for market risk is immaterial (2021: immaterial). This includes credit risk in respect of the Company's UK Government bond holdings whose risk profile and management is described in section C.3.

There has been no material change to the measures used to assess market risk during the reporting period.

C.2.2 Risk concentration

The Company holds UK Government Bonds and Collective Investment Undertakings. It is thus exposed to a concentration of UK Government Bonds. The Collective Investment Undertakings are invested in liquidity funds.

C.2.3 Risk mitigation

The Company manages market risk within its market risk framework, within local regulatory constraints and in line with established Group policy. The management of market risk is overseen by the Asset Liability Committee ("ALCO") and the Board.

The Company did not have any derivatives during the year or at year-end.

C.2.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.2.5 Additional information

There is no significant impact on the Company's exposure to market risk.

C.3 Credit Risk

C.3.1 Exposure

The Company's exposure to credit risk arises from the risk that it will incur a financial loss from the default or failure of third parties to meet their payment obligations to the Company, or variations in market values as a result of changes in expectations related to these risks.

The Company's approach to managing credit risk recognises that there is a risk of adverse financial impact resulting from fluctuations in credit quality of third parties including default, rating transition and credit spread movements. The Company's credit risks arise principally from exposures to UK Government Bonds, insurance debtors, reinsurance counterparties and bank deposits.

The Company's management of credit risk includes implementation of credit risk management processes as part of the wider risk framework (including limits frameworks), and reporting and monitoring of exposures against pre-established risk criteria. The management of credit risk is overseen by the ALCO and the Board.

Risk mitigation techniques are used where and when deemed appropriate. These are utilised where possible to remove residual unwanted risks, as well as to bring or keep exposure limits within appetite.

The principal basis used to measure the Company's exposure to credit risk is the SCR. QRT S.25.01 (Appendix F.1.7) shows that the Company's undiversified SCR for credit risk is £3,164 thousand (2021: £2,474 thousand). Counterparty risk relates to the risk associated with reinsurers and insurance debtors. The Company is additionally exposed to the credit risk associated with UK Government Bonds included in the market risk SCR reported in the QRT as described in section C2.1. There has been no material change in the Company's counterparty risk exposure over the reporting period.

The following metrics are also used when measuring and assessing its credit risk exposure and to support risk management actions and investment decisions:

- Maximum exposure: credit exposure of the Company's financial assets to counterparties;
- External credit rating: available Moody, Standard & Poor and Fitch ratings;

There has been no material change to the measures used to assess credit risk during the reporting period.

The overall credit quality of the Company's financial investments is strong. At 31 December 2022, all Government Bonds were held with the UK Government and valued at £47,332 thousand (2021: £48,985 thousand). Similarly, at 31 December 2022, reinsurance assets all have external credit ratings of A- or above. Collective Investment Undertakings are held with highly rated banking institutions or liquidity funds.

C.3.2 Risk concentration

The Company has exposure to its immediate parent AIL via the reinsurance quota share arrangement discussed in section C.1.1. At 31 December 2022, the reinsurance asset recoverable from AIL is £92,169 thousand (2021: £87,192 thousand). This asset is neither impaired nor

overdue. As at 31 December 2022, and after allowing for Deferred Acquisition Costs (DAC), this counterparty risk exposure is legally offset against a creditor balance with AIL associated with future premium payments. The Company's exposure to AIL as at 31 December 2022, net of DAC and creditor balances, is negative £(15,632) thousand (2021: negative £18,962 thousand). The Company is also a named party to Group wide external catastrophe reinsurance arrangements, and hence could independently access external catastrophe reinsurance recoveries due.

The Company's exposure to receivables of £59,312 thousand at 31 December 2022 (2021: £65,889 thousand) primarily comprises amounts due from insurance contract holders which are neither impaired nor in the main overdue.

C.3.3 Risk mitigation

As described in section C3.1, the Company has in place a credit control framework to manage credit risk.

In accordance with the requirements of the Group Financial Risk Mitigation Business Standard the Company assesses and documents the effectiveness of arrangements to mitigate credit risk are assessed and documented. On-going monitoring is carried out by reporting management information to the ALCO and Board, against pre-defined trigger points, to enable appropriate oversight and to prompt action if effectiveness deteriorates.

C.3.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.3.5 Additional information

The Company's exposure to credit risk arises primarily through its reinsurance arrangements. There has been no significant impact on the credit risk exposure to date.

C.4 Liquidity Risk

C.4.1 Exposure

The Company's exposure to liquidity risk arises from the risk that its liabilities cannot be settled, in a timely and cost-effective manner, as they fall due because of insufficient liquid assets. Liquidity risk may arise from uncertainty of the value and timing of liabilities or the ability to realise assets to produce cash to meet obligations. The Company assesses liquidity risk under a range of scenarios and various levels of liquidity stress. Sources of liquidity risk include:

- Insurance underwriting e.g. catastrophe claims arising from adverse weather events;
- · Variances of actual operational cash flow from shorter-term forecasts; and
- Timing mismatches between claims payments, premium income and reinsurance recoveries.

The principal bases used to measure and assess the Company's exposure to liquidity risk are absolute liquidity coverage relative to predefined appetites and the quantum of certain liquid assets. These are calibrated to ensure sufficient liquidity to meet expected liquidity requirements following an extreme liquidity-specific stress events covering both short-term and long-term stress scenarios.

There has been no material change to the measures used to assess liquidity risk during the reporting period.

There were no material changes in the Company's exposure to liquidity risk throughout the year and the Company's liquidity profile was maintained within appetite.

C.4.2 Risk concentration

The credit limit framework described in section C.3.1 above also avoids concentrations of liquidity risk by preventing investment in a restricted number of issuers, asset classes and sectors. The Company's has set its liquidity risk appetite to ensure it has sufficient liquid funds to meet its expected obligations as they fall due.

C.4.3 Risk mitigation

The Company manages its liquidity risk by considering the liquidity impact before accepting new risks and managing its existing liquidity profile by:

- Monitoring of projected short-term cash flow needs;
- Setting liquidity risk appetites which require that sufficient liquid resources be maintained to cover net outflows in a stress scenario;
- Defining trigger levels that enable action to be taken before those levels are breached; and
- The Company's immediate parent, AIL, maintaining a Capital and Liquidity Management Action Plan (CLMAP) which details management actions to address capital and/or liquidity requirements in a significant stress scenario.

The Company monitors the effectiveness of liquidity risk mitigation techniques as follows:

- The internal controls that enable effective liquidity risk management are subject to assurance testing as part of wider testing undertaken within AIL to ensure they operate effectively; and
- Liquidity positions are regularly reported to and monitored by the ALCO and Board against pre-defined trigger points to enable appropriate oversight and actions to take place if effectiveness deteriorates.

C.4.4 Expected Profit Included in Future Premium (EPIFP)

The amount of EPIFP, calculated in accordance with Article 1 of the SII regulations and included within the valuation of the Company's Technical Provisions as at 31 December 2022 is £nil thousand (2021: £nil thousand). (See the Own Funds QRT S.23.01.01, Appendix F.1.6.).

C.4.5 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.4.6 Additional information

There is no significant impact on the Company's exposure to liquidity risk.

C.5. Operational Risk

C.5.1 Exposure

The Company's exposure to operational risk arises from the risk of direct or indirect loss, caused by inadequate or failed internal processes, people and systems, or external events including changes in the regulatory environment. The Company has a limited appetite for operational risk and aims to reduce these risks as far as commercially sensible.

Conduct risk, an element of operational risk, is where the Company does not achieve positive or fair customer outcomes. Management of conduct risk continues to be a key priority for the Company across the whole lifecycle of its products, and throughout the end to end journey of its customers, with robust governance and metrics embedded across the organisation.

The Company also seeks to manage its exposure to reputational risk, which is the risk of loss to the Company's franchise value from damage caused to the Company's brands or reputation. Examples of factors, regardless of whether authenticated or not, which could damage the Company's brands or reputation include litigation, employee misconduct, operational failures, the outcome of regulatory investigations, media speculation and negative publicity, disclosure of confidential client information or inadequate services.

As part of the wider Group strategy of digital customer interaction, its use of advanced data analytics and the increasing cyber security threat, together with regulators' attention to conduct issues, the Company has increased its inherent exposure to risks such as data theft, conduct breaches and customer service interruption arising from IT systems failure. The Company and its parent have sought to contain and reduce exposure to these risks through on-going investment in programmes to improve IT security and resilience, disaster recovery, data governance and outsourcing. The Company has an Operational Risk and Control Management Framework, which integrates the results of the risk identification and assurance activities carried out across the Company's three lines of defence.

Operational risks are initially identified through the Common Operational Risk Register (CORR) and assessed against implemented controls. Residual risk, outside tolerance, is given prioritised management action to reduce it within tolerance. Operational risk is quantitatively assessed on the basis of financial loss and misstatement. Potential reputational and conduct impacts are qualitatively assessed. There has been no material change to the measures used to assess operational risk during the reporting period.

QRT S.25.01 (Appendix F.1.7) shows that the Company's undiversified SCR for operational risk is £1,112 thousand (2021: £816 thousand). The Company also produces specific conduct risk management information used to measure and analyse its exposure to conduct risk.

The have been no material changes, during the year, to the Company's exposure to operational risk.

C.5.2 Risk concentration

The Company's products are marketed under the 'Barclays' brand, enabling leverage on the strength of that brand and supporting delivery of the Company's business strategy. Whilst reputational risk is mostly borne by the Barclays brand, the Company is vulnerable to any operational failures that adversely impact public perception of the 'Barclays' brand.

C.5.3 Risk mitigation

Operational risks are considered by the Company to be preventable and are managed through business controls. The Company's operational risk strategy is to improve its business processes to:

- · Reduce operational risk and associated losses, thereby improving cost to income ratio and variability in financial performance;
- Improve customer outcomes and employee satisfaction; and
- Sustain customer confidence and a positive regulatory reputation.

The Group's business standards (which apply to the Company) set out the minimum control objectives and controls that each business area is required to operate. Operational risk tolerances are quantitative boundaries that constrain specific risk-taking activities at an operational level.

The Company records and analyses operational risk events to understand the root cause and ensure remedial action is taken, lessons are learnt and, if the event impacts customers, they are treated fairly. This includes risk events that do not give rise to a financial loss, such as near misses or fortuitous gains. This assessment enables the Company to highlight areas for improvement, implement corrective actions to avoid recurrence, and improve its understanding of operational risk.

The Company has identified business critical functions and has exit and termination plans and business continuity and disaster recovery plans in the event of supplier failure. These plans are reviewed at least annually.

The Company's three lines of defence all monitor the effectiveness of the controls that are in place against operational risk. Further details of the three lines of defence are included in section B.1.1, including the specific roles and responsibilities of each line. Operational risk is overseen by the Board.

C.5.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.6 Other Material Risks

The Company has no material information to disclose regarding other material risks.

C.7 Any Other Information

C.7.1 Stress and scenario testing and sensitivity analysis

Stress and Scenario Testing (SST) is a fundamental element of the Company's Risk Management Framework which is embedded within the Company's decision-making, strategy and planning activities. SST provides insight into key risk exposures and dependencies of the Company; considering resilience of potential changes to these exposures and dependencies; and anticipating a range of possible outcomes. The evaluation of the potential impacts on the Company's capital and liquidity positions enables the Company to identify and prepare for appropriate ways to mitigate and manage the realisation of such impacts.

The Company carries out a range of sensitivity tests (where one risk factor, such as interest rates, is assumed to vary) and scenario tests (where combinations of risk factors are assumed to vary) to evaluate their impact on the business and to enable identification of plausible management actions to mitigate such impacts.

C.7.1.1 Stress and scenario testing

The SST completed for the Company, has considered potential impacts from the most significant risks to the Company of counterparty credit risk (arising from both the quota share arrangement in place with its parent company, AIL and the participation in the Group catastrophe reinsurance programme) and operational risks (arising from outsourcing operations and internal failings).

The outcome of this SST demonstrates that the Company is resilient to a range of potential adverse events and that the Company has management actions that could be executed in a timely manner, to mitigate the potential impacts from Company-specific or market-wide events. The Company also considers, and is inherently considered within, the SST that is completed by its immediate parent company, AlL.

A range of assumptions are made in the development of SST and the measurement of resilience to such events. These assumptions are defined by suitable experts and, where applicable, by the Regulators.

C.7.1.2 Sensitivity analysis

Management use sensitivity analyses to assess a range of single factor standalone impacts of differing levels of severity on the capital and liquidity positions of the Company and to ensure that the Company has a sufficient range of plausible management actions that could be executed in a timely manner to mitigate the potential impacts.

The sensitivity analysis performed by the Company includes consideration of the sensitivity of its SII cover ratio, determined according to SII Regulations, to a range of economic assumptions.

For the Company, this includes consideration of impacts from changes in interest rates and changes in reinsurer ratings. The results of these analyses demonstrate that, after consideration of any management actions that may be required, in extreme scenarios, the Company retains a SII surplus. This limited impact is primarily driven by the asset holdings, which are predominately UK Government Bonds and Collective Investment Undertakings with holdings in liquid funds and the extensive reinsurance arrangements in place.

C.7.2 Prudent Person Principle

The Company ensures that its assets are invested in accordance with the Prudent Person Principle as set out in Article 132 (Directive 2009/138/EC) and in the PRA Supervisory Statement (SS1/20) through the collective application of its risk policies and business standards. These ensure that the Company invests in assets whose risks it can properly identify, measure, monitor, manage, control and report, and appropriately take into account in the assessment of its overall solvency needs having regard to the term and nature of its liabilities. The Company's Asset Liability Management Business Standard and certain provisions of the Investment Management Business Standard contain mandatory requirements to ensure that the Company develops its own set of key risk indicators and takes into account the risks associated with its investments without relying only on the risk being adequately captured by the capital requirements. Given the relatively small value of the Company's retained liabilities, it achieves this by investing in low-risk, short term UK Government Bonds and Collective Investment Undertakings with holdings in liquid funds.

Gresham Insurance Company Limited Solvency and Financial Condition Report 2022

D. Valuation for Solvency Purposes

In this Chapter

- D.1 Assets
- D.2 Technical Provisions
- D.3 Other Liabilities
- D.4 Alternative Methods of Valuation
- D.5 Any Other Information

20

D. Valuation for Solvency Purposes

The 'Valuation for Solvency Purposes' section of the report provides a description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset and liability class.

The Company's IFRS balance sheet is presented in column (b) of the following table, in accordance with the classification of assets and liabilities used in its financial statements. The captions used in the table are from the balance sheet QRT S.02.01, rather than the financial statements. The references given in column (a) are to relevant accounting policies and notes provided in the financial statements.

A number of reclassifications, required to align the Company's IFRS balance sheet as shown in its financial statements, to the classifications required for the prescribed format of the SII balance sheet QRT, are given in column (c). The most significant reclassifications are:

- Under the SII Regulations cash flows relating to reinsurance premiums are included within Reinsurance Recoverables, and cash flows
 relating to premiums, and profit share commissions and policyholder tax are included within Technical Provisions. In the IFRS balance
 sheet these amounts are included within reinsurance payables, insurance and intermediaries receivables and other liabilities
 respectively.
- Amounts payable to Group companies under IFRS, are reclassified within the SII balance sheet to the relevant underlying nature of the balance; and
- Investments including cash equivalents are reclassified under SII.

The Company's assets and liabilities, as valued under IFRS and reclassified in line with SII Regulations, are shown in column (d). The Company's SII balance sheet is summarised in column (e) and detailed in the balance sheet QRT S.02.01 included in Appendix F.1.1. Differences between the valuation of the Company's assets and liabilities under SII and IFRS are presented in column (f).

Where the valuation of assets and liabilities is the same under IFRS and SII, a description of the bases, methods and main assumptions can be found in the accounting policies and notes of the Company's financial statements. If the valuation is materially different, a description of the bases, methods and main assumptions used under SII is given in Sections D.1, D.2.1 and D.3 below.

Assets and other liabilities have been valued, according to the requirements of the SII Regulations, at the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. The value of other liabilities is not adjusted to take account of the impact of changes in own credit standing of the Company.

The Company applied the following hierarchy of valuation approaches:

- 1. Quoted market prices in active markets for the same assets or liabilities;
- 2. Quoted market prices in active markets for similar assets and liabilities (with adjustments to reflect differences where necessary);
- 3. Alternative methods of valuation.

The Company considers markets to be active where transactions take place with sufficient frequency and volume for pricing information to be available on an ongoing basis. Where the Company has concluded that markets are not active, alternative methods for valuation are used. The assets classified as Level 1 and Level 2 under IFRS 13, are deemed as market consistent under SII. The assets classified as Level 3, for which there is no active market, are considered to use alternative valuation methods under SII. The Company has not used any alternative methods of valuation.

Business and Performance System of Governance Risk Profile Valuation for Solvency Purposes Capital Management Other Information Summary

Balance Sheet - IFRS and SII

Excess of assets over liabilities		15,074	_	15,074	16,178	1,104
Liabilities		(230,424)	110,133	(120,291)	(77,065)	43,226
Other liabilities	18	(4,704)	(7,334)	(12,038)	(12,038)	
Reinsurers share of DAC	N & 18	(16,602)	(1,393)	(17,995)	_	17,995
Accruals	18	(29,823)	29,823	_	_	_
Current tax liabilities	Q & 16	_	_	_	_	_
Amounts due to Group companies	M & 17	(2,820)	2,820	_		_
Payables (trade, not insurance)	M & 17		(4,077)	(4,077)	(4,077)	_
Reinsurance payables	M & 17	(73,505)	65,247	(8,258)	(8,258)	_
Insurance and intermediaries payable	M & 17	(2,272)	_	(2,272)	(2,272)	_
Debts owed to credit institutions	M & 17	(1,541)	_	(1,541)	(1,541)	_
Payables and other financial liabilities					(301)	(301)
Deferred tax liabilities	110(11	(55,151)	25,010	(, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(367)	(367
Technical provisions	H & 14	(99,157)	25,046	(74,111)	(48,514)	25,596
Assets		245,498	(110,133)	135,364	93,243	(42,121
Prepayments and accrued income	0 0 20	1,264	348	1,612	1,612	_
Cash and cash equivalents	0 & 20	22,393	(21,900)	493	493	_
Reinsurance	L & 10	5,196	408	5,604	5,604	
Receivables Insurance and intermediaries	L & 10	54,116	(54,116)	_		_
Reinsurance recoverables	I & 15	98,599	(57,114)	41,485	15,962	(25,523
Collective investment undertakings	10.15	- 00 500	21,900	21,900	21,900	(05.500
Bonds	K&9	47,332	341	47,673	47,673	_
Financial investments						
Deferred acquisition costs	N & 11	16,598		16,598	_	(16,598)
As at 31 December 2022 £000s	(a)	(b)	(c)	(d) =(b)+(c))	(e)	(f) =(e)-(d)
	Note in financial statements	to financial statements	balance sheet categories	Reclassified IFRS balance sheet	SII balance sheet	Valuation differences between SII and IFRS
		IFRS balance sheet classified according	Reclassification of IFRS balances to SII	•		

D.1 Assets

Assets have been valued according to the requirements of the SII Directive and related guidance; the basis of the SII valuation principle is the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. A description of the basis of valuation under SII along with valuation differences between the SII bases and the IFRS financial statements, by asset class, is provided below; if the valuation method has been described in the financial statements it has not been included in this section.

D.1.1 Deferred acquisition costs

Deferred acquisition costs are recognised under IFRS reporting and deferred to the extent they are expected to be recoverable out of future margins in revenues on those contracts. Under SII these are not recognised and are therefore valued at £nil in the SII balance sheet. The associated cash flows are included in the valuation of SII Technical Provisions.

D.1.2 Collective investment undertakings

The Company's collective investment undertakings are all invested in highly liquid investments that are readily convertible into cash and valued on the basis of the liquid investments they hold. The Company's collective investment undertakings are subject to an insignificant risk of change in value.

In the IFRS financial statements collective investment undertakings are valued at fair value. This is consistent with SII.

D.1.3 Reinsurance recoverables

Reinsurance recoverables are calculated as the probability-weighted average of discounted future cash flows relating to reinsurance contracts, adjusted for the expected losses due to counterparty default. Although established separately, reinsurance recoverables are valued on the same basis and using the same methodology and assumptions used to derive Technical Provisions - Best Estimate Liabilities, as described in Section D.2, subject to the following:

- Internal expenses are only allowed if they are recoverable under the reinsurance agreement;
- Where the timing of recoveries diverges from that for payments a separate projection is used;
- · Allowance for risk of default depends on the credit rating and exposure to the reinsurance counterparty; and
- · Reinsurance assets take into account reinsurance commissions.

Reinsurance recoverables, consistent with the calculation of Technical Provisions - Best Estimate Liabilities, includes expected recoveries from pre-inception contracts where they occur within the premium or claims provisions.

Cash flows relating to future reinsurance arrangements comprise both expected recoveries and expected reinsurance premium payments. This means reinsurance contracts which are expected to be written are taken into account and thus assumptions in relation to the likely future reinsurance purchasing decisions are required.

The Company has a significant exposure to its parent company, AIL, arising from the quota share reinsurance agreement. Further details are set out in Section C.3.2.

The material differences between the SII and IFRS valuation bases for reinsurance recoveries are as follows:

- Only reinsurance cash flows relating to long tailed claims reserves are discounted under IFRS whereas all reinsurance cash flows are discounted under SII.
- The rate used to discount PPO cash flows is lower under SII than the equivalent rate used under IFRS.
- The unearned reinsurance premium reserve established under IFRS is replaced with a best estimate reinsurance premium provision. This is offset by the release of deferred reinsurance commissions from other liabilities (see section D.3.2).
- The SII valuation includes the additional reinsurance premium that is expected to be paid for reinsurance to cover business incepted at the valuation date. This is not accounted for under IFRS.

The Company does not have any Special Purpose Vehicles.

D.1.4 Prepayments

Prepayments are classified as Other Assets on the SII Balance Sheet. Prepayments are valued at their fair value, which is considered to be the same as their cost.

D.1.5 Changes made to recognition and valuation bases and estimations during the reporting period

There were no changes made to the bases used to recognise and value assets, or to their estimations during the reporting period.

D.1.6 Deferred tax assets and liabilities

Deferred tax is determined on a non-discounted basis in accordance with International Accounting Standard (IAS) 12, principles on temporary differences between the economic value of assets or liabilities on the SII balance sheet and their tax base.

Deferred tax assets and liabilities are recognised separately on the Solvency II balance sheet to the extent that deferred tax asset cannot be offset against corresponding deferred tax liabilities.

The deferred tax balances in the Solvency II balance sheet differ from those already recognised in the IFRS balance sheet as a result of the differences between the IFRS and Solvency II balance sheet valuation and consequential impact on recognition of deferred tax assets. The largest impact arises from the derecognition of IFRS deferred acquisition costs and deferred income and results in the net deferred tax liability of £367 thousand.

D.2 Technical Provisions

This section provides a definition of SII Technical Provisions, the methodology and main assumptions used in the valuation of the SII Technical Provisions, the total value of SII Technical Provisions split by material lines of business, a comparison of the valuation of SII Technical Provisions with IFRS Technical Provisions and a description of the level of uncertainty in Technical Provisions.

D.2.1 Valuation of Technical Provisions

SII Technical Provisions are summarised in the following table. All figures are gross of reinsurance. They are also detailed in the QRT S.17.01 (Non-life Technical Provisions) and S.12.01 (Life Technical Provisions), see Appendix F.1.3.

	Best Estimate		Technical
As at 31 December 2022 £000s	Liabilities	Risk Margin	Provisions
Line of Business			
Motor vehicle liability & Other Motor insurance	2,022	2	2,024
Fire and property damage	40,396	184	40,580
General liability insurance	1,585	1	1,587
Non-life insurance obligations	44,004	188	44,193
PPOs other than health insurance	4,322	_	4,322
Life insurance obligations	4,322	_	4,322
Total	48,326	188	48,514

Whilst the Company only conducts non-life insurance activities, it also has life insurance obligations in the UK in relation to annuities stemming from non-life insurance contracts (PPO). PPO are classified as Technical Provisions - Life (excluding health and index-linked and unit-linked), within the prescribed format of the SII Balance Sheet.

An explanation of the differences between the SII valuation of Technical Provisions and the valuation in the Company's financial statements under IFRS is given in section D.2.3.

D.2.1.1 Non-life Best Estimate Liabilities

The following general principles apply to the valuation of Best Estimate Liabilities for non-life and health (similar to non-life) business:

- A Best Estimate is one that represents the expected outcome from the range of possible outcomes for the future and is reasonable and realistic taking account of all the uncertainties involved.
- A consistent approach has been applied across all non-life and health (similar to non-life) business.
- The calculation of Technical Provisions is performed on a going concern basis. This means that it can be assumed that contracts run to their conclusion and as a result a proportion of expected future costs will be covered by future business.

The Company's Best Estimate Liabilities are valued based on the present value of future cash flows discounted using relevant risk-free interest rates adjusted for the Prudential Regulation Authority ("PRA") prescribed credit risk adjustment and Volatility Adjustment at the valuation date. The cash flows that are considered when calculating the Best Estimate Liabilities derive from:

- In-force and expired contracts;
- Contracts that have not yet incepted but that the Company has an obligation to enter into at the valuation date (pre-inception contracts);
- Future cancellations or endorsements by the policyholder.

Best Estimate Liabilities comprise a claims provision and a premium provision. The claims provision includes cash flows relating to events that occurred before the valuation date, whether reported or not. The cash flows include premiums, net claims costs and expenses. The premium provision includes cash flows relating to future claim events that have not yet occurred, but that are covered by existing contracts and legally binding pre-inception contracts. The cash flows include premiums, net claims and expenses, in respect of future claim events. Where future premium cash flows are expected to exceed projected future claim and expense cash flows, the premium provision is negative as is the case for Fire and Other Damage to Property.

When modelling these cash flows the inflows are considered separately from the outflows. Claims costs take into account recoveries from salvage and subrogation. Expenses include administrative, investment management, loss adjustment and acquisition expenses including commissions and premium taxes.

Claims costs

The ultimate cost of outstanding claims is estimated using a range of standard actuarial claims projection techniques. The main assumption underlying these techniques is that the Company's past claims experience can be used as a basis to project future claims. Therefore, these methods extrapolate the development of paid and incurred losses, average costs per claim and claim numbers based on the observed development of earlier years. The recent period of elevated claims inflation and supply chain disruption has distorted historic development patterns. The Company has developed bespoke inflation models to help quantify these impacts. Explicit overlays can then be made to the outputs from the standard reserving tools where necessary. The estimation of ultimate claims costs is done at the level of homogeneous risk groups. These groups are mapped to SII lines of business.

Qualitative judgement is used to reflect changes in external factors such as public attitudes to claiming, economic conditions, levels of claims inflation, judicial decisions and legislation, as well as internal factors such as portfolio mix, policy conditions and claims handling procedures.

Premium provisions

Premium provisions are estimated by selecting an exposure measure and using that to establish the unearned and pre-inception exposure. Claims cost projections are set for each future period using trends in historic claims data adjusted for known anomalies in the data that are not expected to be repeated in the future, changes in mix and volume of business and to allow for the impact of projected claims inflation. These cost projections are then applied to the predicted exposure to determine the cash flows.

Expenses

Expenses are adjusted for expense and claims inflation and allocated between the claims and premium provisions. They are analysed by homogeneous risk group or at a minimum by SII line of business. Future administrative costs and commission payments are projected using best estimate expense forecasts. Investment expenses are modelled as a percentage of Technical Provisions. Future unallocated loss adjustment expense provisions are set in relation to expected claims levels.

Events Not in Data (ENID)

ENID are events not deemed to be captured by the data which need to be separately allowed for within the best estimate calculations to take appropriate account of uncertainty. Two types of ENID are considered: "known unknowns", which are possible future scenarios that can be anticipated and "unknown unknowns", which are future scenarios that are completely unexpected. No allowance is made for "unknown unknowns" as by definition, they cannot be known or quantified.

Allowances for "known unknowns" are made using scenario analysis to cover any foreseeable event with a potentially material impact. A core list of events is specified which are considered as the starting point for the analysis. ENID are considered both at SII lines of business level, and at portfolio level with allocations to SII lines of business, depending on the scenario being considered.

Discounting

All cash flows are discounted using the appropriate SII yield curve in the relevant currency, as published by the PRA. The yield curve is based on the risk free rate at the valuation date and is adjusted by the PRA for prescribed credit risk adjustment (which may be either zero or non-nil) and Volatility Adjustment. Payments are assumed to occur either mid-month or mid-year. Cash flows are modelled in monthly time intervals for the first 10 years and annually thereafter.

Future management actions

There are no future management actions assumed in the calculation of the Company's gross of reinsurance Best Estimate Liabilities as at 31 December 2022.

D.2.1.2 PPO Best Estimate Liabilities

The Company's Best Estimate Liabilities for PPO, in common with non-life business, are valued based on the present value of future cash flows discounted using the relevant risk-free interest rate adjusted for the PRA prescribed credit risk adjustment and Volatility Adjustment at the valuation date. The cash flows that are considered when calculating the Best Estimate Liabilities for PPO derive from:

- Payment of claims benefits: with the majority of PPO providing payments relating to care needs of the claimant, with a smaller number providing loss of earnings payments; and
- · Expenses: these are relatively small (compared to the size of claims benefits) administrative costs in relation to each PPO.

PPO Best Estimate Liabilities use life insurance actuarial methods and techniques to estimate appropriate assumptions for each individual claimant.

Discounting

PPO cash flows are discounted using the appropriate SII yield curve adjusted for the PRA prescribed credit risk adjustment and Volatility Adjustment. The methods are consistent with those applied to non-life cash flows.

Longevity assumptions

Assumptions are made in relation to future longevity. These assumptions are updated annually and based on the latest general mortality assumptions for the population as a whole (including future expected changes in mortality), as well as any impairment to life expectancy on individual PPO based on independent medical opinions.

Inflation assumptions

PPO payments escalate based on indices specified at the time of settlement of the PPO. The majority of PPO claims escalate based on an Annual Survey of Hours and Earnings index (ASHE) with a smaller number escalating in line with the Retail Price Index ("RPI"). Assumptions are therefore required for the future escalation of these indices. The Company assumes that, over the longer term, the future escalation of the ASHE indices will be linked to RPI within the UK economy and uses market consistent views of future RPI inflation as the basis to project future ASHE inflation. Adjustments are then made to allow for any expected differences between future ASHE inflation and future RPI inflation.

D.2.1.3 Risk Margin

The Risk Margin is an estimate of the amount, in addition to the Best Estimate Liability, that a third party would expect to receive in order to assume ownership of the Company's insurance obligations. The Risk Margin calculation takes material underwriting, non hedgeable

market (except interest rate), credit and operational risk into account. Once calculated it is allocated to each SII line of business, although on materiality grounds some SII lines of business are allocated no Risk Margin.

The Company's Risk Margin is £188 thousand (2021; £149 thousand) as at 31 December 2022.

D.2.1.4 Simplifications

Best Estimate Liabilities

In some areas of the calculation of the SII Best Estimate Liabilities, simplified methods have been used. The simplifications used have been assessed and have no material impact on the value of SII Best Estimate Liabilities. Where simplified methods are used, these are documented and justified in the Company's reserving reports and documentation. The main simplifications within the calculation of SII Best Estimate Liabilities are:

- The Company's Best Estimate Liabilities include a provision in relation to ENIDs. For the purposes of discounting cashflows, it is assumed that ENIDs have the same cashflow profile as other claims.
- Cashflows are modelled in monthly time intervals for the first 10 years and annually thereafter. For the purposes of discounting, all payments are assumed to occur mid-month or mid-year as dictated by the time intervals used.
- When calculating provisions for potential reinsurer default, reinsurance assets are grouped by reinsurer counterparty credit rating and within each credit rating the same probabilities of default are assumed.
- · Gross premium debtors are split by class of business and payment date based on the split of written premium.
- The volume of Legally Obliged Unincepted business has been estimated based on a proportion of January's planned written premium.

D.2.1.5 Material changes in the relevant assumptions compared to the previous reporting period

At 31 December 2022 profit commission accruals, other than overdue amounts, are reported within SII Best Estimate Liabilities. In previous reporting periods profit commission accruals related to historic exposure were reported within other liabilities

There were no other material changes in the relevant assumptions made in the calculation of Technical Provisions compared to the previous reporting period.

D.2.2 Level of uncertainty

The actual cost of settling insurance obligations may differ from the Best Estimate Liabilities because experience may be worse than assumed or future claims inflation may differ from that expected. There are a number of potential developments that would have a material adverse impact on the Best Estimate Liabilities value including:

- · Catastrophic weather events;
- · Unanticipated legislative changes; and
- · Unanticipated inflation.

Specific areas of uncertainty are:

- Given the nature of the Company's business, on a gross of reinsurance basis the uncertainty around future weather claims experience is
 the largest risk the Company is exposed to. The Company has extensive reinsurance in place against these claims so net of reinsurance
 the level of uncertainty is reduced.
- Gresham's has extensive reinsurance in place which materially reduces the level of uncertainty.

D.2.3 Material differences between the SII and IFRS valuation bases

The following table summarises gross of reinsurance SII Technical Provisions by material line of business and compares these to IFRS reclassified Technical Provisions.

Total	48,326	188	48,514	74,112	25,597
Life (excluding health and index-linked and unit-linked) (PPO)	4,322	_	4,322	4,602	281
– General liability insurance	1,585	1	1,587	6,517	4,930
– Fire and property damage	40,396	184	40,580	60,821	20,241
 Motor vehicle liability & Other Motor insurance 	2,022	3	2,026	2,172	146
Non-life insurance obligations	44,004	188	44,193	69,509	25,317
Technical Provisions as at 31 December 2022 £000s	Best Estimate Liabilities	Risk Margin (unaudited)	Technical Provisions	IFRS reclassified Technical Provisions	Difference between SII and IFRS reclassified Technical Provisions

The material differences between the SII and IFRS valuation bases are summarised below:

- The unearned premium reserve established under IFRS is replaced with a Best Estimate premium provision which incorporates the expected cost of claims and expenses on the unearned periods of exposure. This leads to a lower premium provision under SII than the equivalent unearned premium reserves under IFRS and is the most material difference between SII and IFRS Technical Provisions in the table above. This difference has a material impact on the Fire and property damage line of business, but immaterial impacts on the other lines of business:
- Only PPO claims are discounted within IFRS provisions, whereas all cash flows are discounted under SII. This difference reduces SII Technical Provisions compared to IFRS provisions and affects all Non-life (excluding health) lines of business;

- An explicit margin for uncertainty is included within IFRS provisions but removed under SII. This impacts all lines of business and reduces SII Technical Provisions compared to IFRS provisions;
- Under SII, provisions are established for Legally Obliged Unincepted Business, whereas these provisions are not included within the IFRS valuation basis. This difference mainly impacts the Fire and property damage line of business. This typically reduces SII technical provisions compared to IFRS provisions to the extent Legally Obliged Unincepted business is profitable.

D.2.4 Volatility Adjustment

The Volatility Adjustment removes temporary distortions in spreads caused by illiquidity in the market or extreme widening of credit spreads, in particular in relation to government bonds. The PRA has approved the Company's application to apply a Volatility Adjustment (PRA reference number: 2191473). The impact of the Volatility Adjustment on Technical Provisions, Basic Own Funds, Eligible Own Funds to meet the SCR, the SCR (unaudited), Eligible Own Funds to meet the Minimum Capital Requirement (MCR) and the MCR is detailed in the Long Term Guarantees and Transitional measures QRT S.22.01 (see Appendix F.1.5). The impact of removing the Volatility Adjustment from gross SII Technical Provisions would be to increase their value by less than £1m.

D.2.5 Other reliefs

No transitional provisions have been applied in the calculation of SII Technical Provisions.

D.3 Other Liabilities

Other liabilities have been valued according to the requirements of the SII Directive and related guidance; the basis of the SII valuation principle is the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. A description of the basis of valuation under SII along with valuation differences between the SII bases and the IFRS financial statements, by material class, is provided below; if the valuation method has been described in the financial statements it has not been included in this section.

The Company's financial statements provide information about contingent liabilities and other risk factors in note 19. The Company has no additional material contingent liabilities to recognise under SII.

D.3.1 Reinsurers share of deferred acquisition costs

Reinsurers' share of deferred acquisition costs of £16,598 thousand (2021: £19,735 thousand), included within other liabilities under IFRS, are not recognised and therefore valued at £nil in the SII balance sheet.

D.3.2 Other liabilities

Other Liabilities comprise accruals and cash flows payable under the quota share arrangement. Other liabilities expected to be settled within one year are valued, on the SII balance sheet, at the amount expected to be paid. Non-current accruals and other liabilities are valued at their fair value, and are not adjusted to take account of the impact of changes in the own credit standing of the Company. In valuing such liabilities, the timing and monetary amount of expected outflow of cash or other resources are determined and these projected cash flows discounted.

Deferred income of £1,393 thousand (2021: £1,428 thousand), included within other liabilities under IFRS, is not recognised and therefore valued at £nil in the SII balance sheet.

D.3.3 Assumptions, judgements and uncertainty

No material assumptions or judgements were applied to, nor is any material uncertainty associated with, the recognition and valuation of other liabilities.

D.3.4 Changes made to recognition and valuation bases and estimations during the reporting period

There were no changes made to the recognition and valuation bases used or to estimations during the reporting period.

D.4 Alternative Methods of Valuation

The Company has not used any alternative methods of valuation.

D.5 Any Other Information

The Company is implementing IFRS 17 insurance contracts from 1 January 2023. The adoption of IFRS 17 significantly impacts the measurement and presentation of the contracts in scope of the standard as set out in detail on pages 14 to 17 of the Company's financial statements. However, the cash flows and underlying capital generation of the Company is unaffected by IFRS 17, and the standard will have no impact on Solvency II performance metrics.

During January 2023, the Company has entered into a contractual agreement with its distribution partner Barclays Bank UK plc that will result in the Company terminating the current business arrangement on a target date in the third quarter of 2023 and acquiring renewal rights to in-force UK household insurance policies in return for an upfront payment to the distribution partner later in 2023. This payment, which will be determined with reference to the number of in force policies at that date, will be funded via capital injection from the parent. Brand migration of these policies from Barclays to Aviva will happen on the acquisition date, with no further new business acquisition into Gresham. The principal activity of the Company going forward will therefore be to administer and manage the in-force UK household insurance policies.

The Company has no other material information to disclose.

Gresham Insurance Company Limited

Solvency and Financial Condition Report

2022

Summary

E. Capital Management

In this Chapter

- E.1 Own Funds
- E.2 Solvency Capital Requirement and Minimum Capital Requirement
- E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement
- E.4 Differences between the Standard Formula and any Internal Model used
- E.5 Non-Compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement
- E.6 Any Other Information

28

E. Capital Management

The 'Capital Management' section of the report describes the objectives, policies and procedures employed by the Company for managing its Own Funds. The section also covers information on structure and quality of Own Funds and calculation of SCR.

E.1 Own Funds

E.1.1 Management of Own Funds

The Company's capital and risk management objectives are closely interlinked and support earnings growth and dividend policy, whilst also recognising the critical importance of protecting policyholder and other stakeholder interests. The Company's primary objective of managing capital efficiently is to optimise the balance between return and risk, whilst maintaining economic and regulatory capital surplus in accordance with approved risk appetites.

In managing its Own Funds the Company also seeks to:

- · Match the profile of its assets and liabilities, taking account of the risks inherent in the business;
- Maintain sufficient, but not excessive, financial strength to support new business growth and satisfy the requirements of its policyholders and its regulator, the PRA;
- Retain financial flexibility by maintaining sufficient liquidity; and
- Allocate capital efficiently, applying it to support value-adding growth and repatriating excess capital to its shareholder through dividends.

Own Funds are monitored via forecasts over a three year planning horizon. A number of stress and scenario tests are used to enable the Company to understand the volatility of its earnings and capital requirement, and therefore manage its capital more efficiently.

There have been no material changes in the objectives, policies or processes employed for managing Own Funds during the year.

E.1.2 Eligible Own Funds

An analysis of the Company's Own Funds by tier is presented in the Own Funds QRT S.23.01.01, (see Appendix F.1.6), and summarised below

Own Funds £000s	Total	Tier 1 (unrestricted)	Total	Tier 1 (unrestricted)
As at 31 December	2022	2022	2021	2021
Ordinary share capital	10,000	10,000	10,000	10,000
Reconciliation reserve	6,178	6,178	2,950	2,950
Total Basic Own Funds	16,178	16,178	12,950	12,950

Tiering analysis

The Company's ordinary share capital and reconciliation reserve are available to absorb losses and have the Tier 1 features of permanence and subordination. As the Company's Articles of Association do not contain any restriction on the right of the Company to cancel dividends or other distributions at any time before they are paid, the Company's ordinary share capital is classified as unrestricted Tier 1.

The Company's Tier 1 Own Funds of £16,178 thousand (2021: £12,950 thousand) increased by £3,228 thousand during the year. This increase is driven by capital generated by the Company's operations during the year.

Reconciliation reserve

The Company's capital comprises ordinary share capital and retained earnings. However, retained earnings are not separately disclosed in Own Funds. They are notionally included in the reconciliation reserve, which reconciles the total excess of assets over liabilities with identifiable capital instruments included in Own Funds.

The table below sets out the constituent parts of the reconciliation reserve:

	£000s	£000s
As at 31 December	2022	2021
SII excess of assets over liabilities	16,178	12,950
Ordinary share capital	(10,000)	(10,000)
Reconciliation reserve	6,178	2,950

Eligibility of tiered capital

The eligibility of tiered capital, to cover the SCR and MCR depends upon the tiering shown above and a number of quantitative limits. The Company's Own Funds satisfy all limits applicable to the SCR and MCR and therefore the eligibility of the Company's capital to cover the SCR and MCR is unrestricted, as shown in the table below.

	£000s	£000s
As at 31 December	2022	2021
Total eligible Own Funds to meet the SCR	16,178	12,950
Total eligible Own Funds to meet the MCR	16,178	12,950

The ratio of eligible Own Funds to the SCR and the MCR is detailed below.

As at 31 December	2022	2021
Ratio of eligible Own Funds to the SCR	336 %	366 %
Ratio of eligible Own Funds to the MCR	470 %	414 %

E.1.3 Material differences between equity on an IFRS basis and Own Funds

The Company's Own Funds are equal to its excess of assets over liabilities on a SII basis. The excess of £16,178 thousand is £1,104 thousand more than the Company's total equity on an IFRS basis. The following table details the material differences between the excess of assets over liabilities on a SII basis and total equity on an IFRS basis.

As at 31 December 2022	£000s £000s	See Section
Total equity on an IFRS basis		15,074
Elimination of deferred acquisition costs	(16,598)	D.1.1
Valuation adjustments to reinsurance recoverables	(25,523)	D.1.3
Valuation adjustments to Technical Provisions	25,596	D.2.3
Elimination of reinsurers share of deferred acquisition costs	16,598	D.3.1
Elimination of deferred income	1,398	D.3.2
Net deferred tax adjustments	(367)	D.1.6
		1,104
Excess of assets over liabilities on a SII basis		16,178

E.1.4 Transitional arrangements and restrictions

The Company's Own Funds are unrestricted and fully transferable.

E.2 Solvency Capital Requirement (SCR) and Minimum Capital Requirement (MCR)

E.2.1 The amount of the SCR and MCR

The Company's SCR as at 31 December 2022 was £4,816 thousand (2021: £3,536 thousand). This is shown in the SCR QRT, S.25.01, see Appendix F.1.7. The final amount of the SCR is subject to supervisory assessment and does not include any regulator-imposed capital addons. The Company's MCR as at 31 December 2022 was £3,445 thousand (2021: £3,126 thousand). This is shown on the MCR QRT, S.28.01, see Appendix F.1.8.

E.2.2 The composition of the SCR

The Company determines its SCR using SF. An analysis by risk module is presented in the table below. Further detail is shown in the SCR QRT, see Appendix F.1.7.

Diversified SCR by material risk category (per the SCR QRT)	_£000s	£000s
As at 31 December	2022	2021
Market risk	115	359
Counterparty risk	3,164	2,474
Underwriting risk	887	296
Diversification between risk categories	(461)	(408
Basic SCR	3,705	2,721
Operational risk	1,112	816
Total SCR	4,816	3,536

Each risk module includes the impact of diversification within that module. The diversification benefit presented in the table above of negative £461 thousand (2021: negative £408 thousand) therefore only includes the benefit of diversification between risk modules. This has increased in year following the reduction in the component risks explained below.

The SCR increase was mainly driven by including the stressed due premium debtor within the counterparty risk and profit commission within the Technical Provisions stressed in Underwriting risk. Market risk has reduced as Gresham holds a single asset, a UK gilt maturing in 2023, which is now a year closer to maturity. This provides a better match to the liabilities than at the previous year-end. Operational risk is capped at 30% of the Basic SCR and increases in line with the other risks.

E.2.3 Simplifications, undertaking specific parameters and matching adjustment (unaudited)

The Company has not used any simplified calculations, undertaking specific parameters or a matching adjustment in the calculation of its SCR.

E.2.4 MCR calculation

The Company's MCR is calculated by applying prescribed factors to its written premium and its net Best Estimate Liabilities. The MCR is subject to two further constraints; it must lie in the range of 25% to 45% of the Company's SCR and it cannot be less than an absolute minimum of €4.0m, converted at the exchange rate applicable at the end of October preceding the year end. The Company's MCR is the absolute minimum which is £3,445 thousand following translation into GBP (2021: £3,126 thousand).

E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement

The Company does not use this option.

E.4 Differences between the Standard Formula and any Internal Model used

The Company does not use an Internal Model (IM).

E.5 Non-Compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement

The Company has complied continuously with both the MCR and the SCR throughout the reporting period.

E.6 Any Other Information

The Company has no other material information to disclose.

Gresham Insurance Company Limited

Solvency and Financial Condition Report

2022

Summary

F. Appendices

In this Section

=.0	Cautionary Statement
F.1.2.2 F.1.3.1	Public Disclosure Quantitative Reporting Templates S.02.01 Balance Sheet S.05.01 Premium claims and expenses (by line of business) [life] S.05.01 Premium claims and expenses (by line of business) [non-life] S.12.01 Technical Provisions [life] S.17.01 Technical Provisions [non-life] S.19.01 Insurance claims [non-life] S.22.01 Impact of transitional measures S.23.01 Own Funds S.25.01 Solvency Capital Requirement S.28.01 Minimum Capital Requirement
=.2 =.3 =.4	Glossary of Abbreviations and Definitions Directors' Statement External Audit

F.0 Cautionary Statement

This announcement contains, and we may make other verbal or written 'forward-looking statements' with respect to certain of the Company's plans and current goals and expectations relating to future financial condition, performance, results, strategic initiatives and objectives (including, without limitation, climate-related plans and goals). Statements containing the words 'believes', 'intends', 'expects', 'projects', 'plans', 'will', 'seeks', 'aims', 'may', 'could', 'outlook', 'likely', 'target', 'goal', 'guidance', 'trends', 'future', 'estimates', 'potential' 'objective', 'predicts', 'ambition' and 'anticipates', and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements.

The Company believes factors that could cause actual results to differ materially from those indicated in forward-looking statements in the announcement include, but are not limited to: the impact of ongoing uncertain conditions in the global financial markets and the national and; international political and economic situation generally (including those arising from the Russia-Ukraine conflict); market developments and government actions (including those arising from the evolving relationship between the UK and the EU); the effect of credit spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings, on the value of our investments; reduce the value or yield of our investment portfolio and impact our asset and liability matching; the impact of changes in short or long-term inflation; the effect of market fluctuations on the value of the assets backing reserves; the amount of allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; changes in, or restrictions on, our ability to initiate capital management initiatives; changes in or inaccuracy of assumptions in pricing and reserving for insurance business (particularly with regard to mortality and morbidity trends, lapse rates and policy renewal rates), a cyclical downturn of the insurance industry; the impact of natural and man-made catastrophic events (including the longer-term impact of COVID-19) on our business activities and results of operations; the transitional and physical risks associated with climate change; failure to understand and respond effectively to the risks associated with environmental, social or governance ('ESG') factors; our reliance on information and technology and third-party service providers for our operations and systems; the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; increased competition in the UK; the impact of actual experience differing from estimates used in valuing and amortising deferred acquisition costs ('DAC'); changes in valuation methodologies, estimates and assumptions used in the valuation of investment securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and human error or from external events and malicious acts (including cyber attack and theft, loss or misuse of customer data); risks associated with arrangements with third parties; our reliance on third-party distribution channels to deliver our products; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of simplifying our operating structure and activities; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other distributors of our products and services; changes to our brand and reputation; changes in tax laws and interpretation of existing tax laws in jurisdictions where we conduct business; changes to International Financial Reporting Standards relevant to insurance companies and their interpretation (for example, IFRS 17); the inability to protect our intellectual property; the policies, decisions and actions of government or regulatory authorities in the UK, the European Union, or elsewhere, including the implementation of key legislation and regulation (for example, FCA Consumer Duty and Solvency II). For a more detailed description of these risks, uncertainties and other factors, please see the Aviva plc Annual report and

The Company undertakes no obligation to update the forward-looking statements in this announcement or any other forward-looking statements it may make. Forward-looking statements in this report are current only as of the date on which such statements are made. The climate metrics used in this document should be treated with special caution, as they are more uncertain than, for example, historical financial information and given the wider uncertainty around the evolution and impact of climate change. Climate metrics include estimates of historical emissions and historical climate change and forward-looking climate metrics (such as ambitions, targets, climate scenarios and climate projections and forecasts). Our understanding of climate change and its impact continue to evolve. Accordingly, both historical and forward-looking climate metrics are inherently uncertain and, therefore, less decision-useful than metrics based on historical financial statements.

This Solvency and Financial Condition Report has been published for information only, it is based on our understanding as at 6 April 2023 and does not provide financial or legal advice. Other than as set out in section F.3 (Directors Statement), the Company, its directors, employees, agents or advisers do not accept or assume responsibility to any person to who this document is shown or into whose hands it may come, and any such responsibility or liability is expressly disclaimed.

Business and Performance System of Governance Risk Profile Valuation for Solvency Purposes Capital Management Other Information Summary

Appendix F.1.1 S.02.01.02 Balance Sheet Amounts in 000s

		Solvency II Value
Assets		C0010
Intangible assets	R0030	
Deferred tax assets	R0040	
Pension benefit surplus	R0050	
Property, plant & equipment held for own use	R0060	
Investments (other than assets held for index-linked and unit-linked contracts)	R0070	69,573
Property (other than for own use)	R0080	
Holdings in related undertakings, including participations	R0090	
Equities	R0100	
- Equities - Listed	R0110	
- Equities - Unlisted	R0120	.= .=
Bonds	R0130	47,673
- Government Bonds	R0140	47,673
- Corporate Bonds - Structured Notes	R0150 R0160	
- Structured Notes	R0170	
Collective Investments Undertakings	R0180	21,900
Derivatives	R0190	21,500
Deposits other than cash equivalents	R0200	
Other investments	R0210	
Assets held for index-linked and unit-linked contracts	R0220	
Loans & mortgages	R0230	
- Loans on policies	R0240	
- Loans & mortgages to individuals	R0250	
- Other loans & mortgages	R0260	
Reinsurance recoverables from:	R0270	15,962
- Reinsurance recoverables - Non-life and health similiar to non-life	R0280	12,136
- Reinsurance recoverables - Non-life excluding health	R0290	12,136
- Reinsurance recoverables - Health similar to non-life	R0300	2.026
- Reinsurance recoverables - Life and health similar to life, excluding health and index-linked and unit-linked - Reinsurance recoverables - Health similar to life	R0310	3,826
- Reinsurance recoverables - Health similar to life - Reinsurance recoverables - Life excluding health and index-linked and unit-linked	R0320 R0330	3,826
- Reinsurance recoverables - Life excluding realth and index-linked and diffi-linked	R0340	3,020
Deposits to cedants	R0350	
Insurance & intermediaries receivables	R0360	_
Reinsurance receivables	R0370	5,604
Receivables (trade, not insurance)		
Own Shares (held directly)	R0390	
Amounts due in respect of own fund items or initial fund called up but not yet paid in	R0400	
Cash and cash equivalents	R0410	493
Any other assets, not elsewhere shown	R0420	1,608
Total assets	R0500	93,240
Liabilities		
	D0510	44 102
Technical provisions - Non-life - Technical provisions - Non-life (excluding health)	R0510	44,193 44,193
- TP calculated as a whole - Non-life (excluding health)	R0520 R0530	44,195
	R0540	44,004
	1 110570	
- Best Estimate - Non-life (excluding health)		188
- Risk margin - Non-life (excluding health)	R0550	188
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life)	R0550 R0560	188
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life)	R0550 R0560 R0570	188
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life)	R0550 R0560 R0570 R0580	188
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life)	R0550 R0560 R0570	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life)	R0550 R0560 R0570 R0580 R0590	
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620	
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630	
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650	
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked)	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0690 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (exch health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700 R0710	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0710 R0710	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0710 R0710 R0720 R0740	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0710 R0720 R0740 R0750	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0710 R0710 R0720 R0740	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700 R0710 R0720 R0740 R0750 R0760	4,322
- Risk margin - Non-life (excluding health) - Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0550 R0560 R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0710 R0710 R0720 R0740 R0750 R0750 R0760 R0770	4,322 4,322 4,322 —

	Business and	System of	Risk	Valuation for	Capital	Other
Summar	y Performance	Governance	Profile	Solvency Purposes	Management	Information

Excess of assets over liabilities	R1000	16,178
Total liabilities	R0900	77,061
Any other liabilities, not elsewhere shown	R0880	12,034
- Subordinated liabilities in BOF	R0870	
- Subordinated liabilities not in BOF	R0860	
Subordinated liabilities	R0850	
Payables (trade, not insurance)	R0840	4,077
Reinsurance payables	R0830	8,258
Insurance & intermediaries payables	R0820	2,271
Financial liabilities other than debts owed to credit institutions	R0810	

Risk Profile Valuation for Solvency Purposes Other Information Business and Performance System of Governance Summary Capital Management

Appendix F.1.2.1

Premiums, claims and expenses by line of business Amounts in 000s

Amounts in 000s			Line of Business for: lif	e insurance obligations			Life reinsuran	ce obligations	
	Health [accepted non proportional reinsurance]	Insurance with profit participation	Unit-linked or index- linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance	Health reinsurance	Life reinsurance	Total
Premiums written	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
	410								
	410								
	420								
	500								
Premiums earned									
Gross - Direct Business R1	510								
Reinsurers' share R1	520								
Net R1	600								
Claims incurred					1				
Gross - Direct Business R1	510					(3,804)			(3,804)
Reinsurers' share	620					151			151
Net R1	700					(3,955)			(3,955)
Changes in other technical provisions									, ,
	710								
Reinsurers' share	720								
Net R1	300								
	900								
•	500								
•	500								
Total expenses R2	500								

Appendix F.1.2.2 S.05.01.02
Premiums, claims and expenses by line of business

Amounts in 000s

				L	ine of Business for: no	on-life insurance an	d reinsurance obligat	ions (direct business a	and accepted proport	onal reinsurance)			
		Medical expense insurance [direct business]	Income protection insurance [direct business]	Workers' compensation insurance [direct business]	Motor vehicle liability insurance [direct business]	Other motor insurance [direct business]	Marine, aviation and transport insurance [direct business]	Fire and other damage to property insurance [direct business]	General liability insurance [direct business]	Credit and suretyship insurance [direct business]	Legal expenses insurance [direct business]	Assistance [direct business]	Miscellaneous financial loss [direct business]
Premiums written		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120
Gross - Direct Business	R0110							98,769	3,055				
Gross - Proportional reinsurance accepted	R0120							30,103	3,033				
Gross - Non-proportional reinsurance accepted	R0130												
Reinsurers' share	R0140							94,622	2,926				
Net _	R0200							4,147	128				
Premiums earned	D0010							105.000	2.275		I		
Gross - Direct Business	R0210							105,899	3,275				
Gross - Proportional reinsurance accepted	R0220												
Gross - Non-proportional reinsurance accepted	R0230												
Reinsurers' share	R0240				16			101,736	3,146				
Net	R0300				(16)			4,163	129				
Claims incurred													
Gross - Direct Business	R0310				1,490			55,842	1,727				
Gross - Proportional reinsurance accepted	R0320												
Gross - Non-proportional reinsurance accepted	R0330												
Reinsurers' share	R0340				(3,052)			56,986	1,762				
Net	R0400				4,543			(1,144)	(35)				
Changes in other technical provisions													
Gross - Direct Business	R0410												
Gross - Proportional reinsurance accepted	R0420												
Gross - Non-proportional reinsurance accepted	R0430												
Reinsurers' share	R0440												
Net	R0500												
Expenses incurred	R0550							1,725	53				
Other expenses	R1200												
Total expenses	R1300												

Summary

		Line	e of Business for: accepted	non proportional reinsur	ance	
		Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance	Total
		C0130	C0140	C0150	C0160	C0200
Premiums written					_	
Gross - Direct Business	R0110					101,824
Gross - Proportional reinsurance accepted	R0120					
Gross - Non-proportional reinsurance accepted	R0130					
Reinsurers' share	R0140					97,548
Net	R0200					4,276
Premiums earned					_	
Gross - Direct Business	R0210					109,175
Gross - Proportional reinsurance accepted	R0220					
Gross - Non-proportional reinsurance accepted	R0230					
Reinsurers' share	R0240					104,899
Net	R0300					4,276
Claims incurred					_	
Gross - Direct Business	R0310					59,059
Gross - Proportional reinsurance accepted	R0320					
Gross - Non-proportional reinsurance accepted	R0330					
Reinsurers' share	R0340					55,696
Net	R0400					3,363
Changes in other technical provisions						
Gross - Direct Business	R0410					
Gross - Proportional reinsurance accepted	R0420					
Gross - Non-proportional reinsurance accepted	R0430					
Reinsurers' share	R0440					
Net	R0500					
Expenses incurred	R0550					1,778
Other expenses	R1200					
Total expenses	R1300					1.778

Risk Profile Valuation for Solvency Purposes Other Information Summary Business and Performance System of Governance Capital Management

Appendix F.1.3.1 S.12.01.02 Life and Health SLT Technical Provisions Amounts in 000s

		Insurance with profit participation	Unit-li	inked or index-linked in	nsurance		Other life insurance			Accepted reinsurance	Total (Life other than health insurance, incl. Unit-Linked)
				Contracts without options and guarantees	Contracts with options or guarantees		Contracts without options and guarantees	Contracts with options or guarantees			
Technical provisions calculated as a whole	R0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0150
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0020										
Technical provisions calculated as a sum of BE and RM Best Estimate											
Gross Best Estimate	R0030								4,322	_	4,322
Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default	R0080								3,826		3,826
Best estimate minus recoverables from reinsurance and SPV - Total	R0090								496		496
Risk Margin	R0100								_		_
Amount of the transitional on Technical Provisions											
Technical Provisions calculated as a whole	R0110										
Best estimate	R0120										
Risk margin	R0130								4 222		4 222
Technical provisions - Total	R0200								4,322		4,322

R0110

R0120 R0130

R0200

Business and Performance

Technical provisions calculated as a sum of BE and RM **Best Estimate**

Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default

Technical provisions calculated as a whole

Gross Best Estimate

associated to TP as a whole

Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default

Best estimate minus recoverables from reinsurance and SPV - Total

Risk Margin

Amount of the transitional on Technical Provisions

Technical Provisions calculated as a whole Best estimate Risk margin

Technical provisions - Total

Appendix F.1.3.2 S.17.01.02 Non-Life Technical Provisions

Amounts in 000s	Direct business and accepted proportional reinsurance												
		Medical expense insurance [direct business]	Income protection insurance [direct business]	Workers' compensation insurance [direct business]	Motor vehicle liability insurance [direct business]	Other motor insurance [direct business]	Marine, aviation and transport insurance [direct business]	Fire and other damage to property insurance [direct business]	General liability insurance [direct business]	Credit and suretyship insurance [direct business]	Legal expenses insurance [direct business]	Assistance [direct business]	Miscellaneous financial loss [direct business]
To desire I was delen a selected at a code of	D0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130
Technical provisions calculated as a whole Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0010 R0050												
Technical provisions calculated as a sum of BE and RM													
Best estimate													
Premium provisions	R0060				1		Ι	5,738	1.4				
Gross	KUU60							5,738	-14				
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140							-22,984	-304				
Net Best Estimate of Premium Provisions	R0150							28,722	290				
Claims provisions													
Gross	R0160				2,022			34,658	1,599				
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240				2,022			31,831	1,571				
Net Best Estimate of Claims Provisions	R0250							2,827	29				
Total Best estimate - Gross	R0260				2,022	_	_	40,396	1,585				
Total Best estimate - Net	R0270							31,549	319				
Risk margin	R0280				2	1	_	184	1				
Amount of the transitional on Technical Provisions							1	1					
Technical Provisions calculated as a whole	R0290												
Best estimate	R0300												
Risk margin	R0310												
Technical provisions - Total Technical provisions - Total	R0320			1	2,024	1		40,580	1,587				
•	KU320				2,024	1		40,560	1,567				
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - Total	R0330				2,022			8,847	1,267				
Technical provisions minus recoverables from reinsurance/SPV and Finite Re - Total	R0340				2	1		31,733	320				

Valuation for Solvency

Purposes

Summary

Other

Information

R0240

R0250 Total R0260 3,695

25,213

38,280

R0240

R0250

R0240

R0250

10.122

26,418

3.948

Risk Profile Valuation for Solvency Purposes Capital Management Business and System of Other Performance Summary Governance Information

Appendix F.1.5 S.22.01.21

Impact of long term guarantees and transitional measures

Amounts in 000s

Technical Provisions Basic Own Funds Eligible own funds to meet Solvency Capital Requirement Solvency Capital Requirement Eligible own funds to meet Minimum Capital Requirement Minimum Capital Requirement

	Amount with LG measures and transitionals	Impact of transitional on technical provisions	Impact of transitional on interest rate	Impact of volatility adjustment set to zero	Impact of matching adjustment set to zero
	C0010	C0030	C0050	C0070	C0090
R0010	48,514			486	
R0020	16,178				
R0050	16,178				
R0090	4,817				
R01 00	16,178				
R0110	3,445				

System of Governance Risk Profile Valuation for Solvency Purposes Capital Management Other Information Business and Performance Summary

Appendix F.1.6 S.23.01.01 Own Funds Amounts in 000s

		Total	Tier 1	Tier 1	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35						
Ordinary share capital (gross of own shares)	R0010	10,000	10,000			
Share premium account related to ordinary share capital	R0030					
Initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual-type undertakings	R0040					
Subordinated mutual member accounts	R0050					
Surplus funds	R0070					
Preference shares Share premium account related to preference shares	R0090 R0110					
Reconciliation reserve	R0130	6,178	6,178			
Subordinated liabilities	R0140	,	, i			
An amount equal to the value of net deferred tax assets	R0160					
Other own fund items approved by the supervisory authority as basic own funds not specified above	R0180					
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as						
Solvency II own funds						
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as	R0220					
Solvency II own funds						
Deductions	D0000					
Deductions for participations in financial and credit institutions Total basic own funds after deductions	R0230	16 170	16 170			
	R0290	16,178	16,178			
Ancillary own funds Unpaid and uncalled ordinary share capital callable on demand	R0300				1	
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual-type undertakings, callable on	R0310					
demand	DOCO					
Unpaid and uncalled preference shares callable on demand A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0320 R0330					
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/ EC	R0340					
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350					
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360					
Supplementary members calls other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370					
Other ancillary own funds	R0390					
Total ancillary own funds - Solo	R0400					
Available and eligible own funds Total available own funds to meet the SCR	R0500	16,178	16,178			
Total available own funds to meet the MCR	R0510	16,178	16,178			
Total eligible own funds to meet the SCR	R0540	16,178	16,178			
Total eligible own funds to meet the MCR	R0550	16,178	16,178			
SCR	R0580	4,817				
MCR	R0600	3,445				
Ratio of eligible own funds to SCR	R0620	3.3587				
Ratio of eligible own funds to MCR	R0640	4.6967				
Reconciliation Reserve		C0060				
Excess of assets over liabilities	R0700	16,178				
Own shares (held directly and indirectly)	R0710					
Foreseeable dividends, distributions and charges	R0720					
Other basic own fund items	R0730	10,000				
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0740	_				
Reconciliation reserve	R0760	6,178				
Expected profits	D0770					
Expected profits included in future premiums (EPIFP) - Life business Expected profits included in future premiums (EPIFP) - Non-life business	R0770 R0780					
Total expected profits included in future premiums (EPIFP)	R0790					

Appendix F.1.7 S.25.01.21 Solvency Capital Requirement - For undertakings using the standard formula Amounts in 000s

Component Description		Gross Solvency Capital Requirement	USP	Simplification s	LAC DT
C0020		C0030	C0090	C0120	C0130
Market Risk	R0010	115		None	None
Counterparty Risk	R0020	3,164	Mana	Nissa	Mana
Life underwriting risk Health underwriting risk	R0030 R0040	37	None None	None None	None None
Non-life underwriting risk	R0040	851	None	None	None
Diversification	R0060	1,112	TVOTIC	None	TVOTIC
Intangible asset risk	R0070				
Basic Solvency Capital Requirement	R0100				
		60100			
		C0100			
Calculation of Solvency Capital Requirement					
Operational risk	R0130	(461)			
Loss-absorbing capacity of technical provisions	R0140				
Loss-absorbing capacity of deferred taxes	R0150	4,817			
		,-			
Capital requirement for business operated in accordance with Art. 4 of Directive	R0160				
2003/41/EC	110200				
Solvency Capital Requirement excluding capital add-on		4,817			
Capital add-ons already set	R0200				
Solvency capital requirement for undertakings under consolidated method	R0210				
Other information on SCR	R0220				
Capital requirement for duration-based equity risk sub-module	R0400				
Total amount of Notional Solvency Capital Requirements for remaining part	R0410				
Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0420				
Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0430				
Diversification effects due to RFF nSCR aggregation for article 304	R0440				
		Approach based on average tax rate			
Approach to tax rate		C0109			
Approach based on average tax rate	R0590	_			
Calculation of loss absorbing capacity of deferred taxes					
LAC DT	R0640				
LAC DT justified by reversion of deferred tax liabilities	R0650				
LAC DT justified by reference to probable future taxable profit	R0660				
LAC DT justified by carry back, current year	R0670				
LAC DT justified by carry back, future years	R0680				
Maximum LAC DT	R0690				

Appendix F.1.8

S.28.01.01

Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Linear formula component for non-life insurance and reinsurance obligations

MCRNI Result

C0010 R0010 3,319,108

	reinsurance/SPV) best estimate and TP calculated as a whole	reinsurance) written premiums in the last 12 months
	C0020	C0030
R0020		
R0030		
R0040		
R0050		
R0060		
R0070		
R0080	31,549	4,276
R0090	319	
R01 00		
R0110		
R0120		
R0130		
R0140		
R0150		
R0160		

Net (of

Net (of

Medical expense insurance and proportional reinsurance Income protection insurance and proportional reinsurance Workers' compensation insurance and proportional reinsurance Motor vehicle liability insurance and proportional reinsurance Other motor insurance and proportional reinsurance Marine, aviation and transport insurance and proportional reinsurance Fire and other damage to property insurance and proportional reinsurance General liability insurance and proportional reinsurance Credit and suretyship insurance and proportional reinsurance Legal expenses insurance and proportional reinsurance Assistance and proportional reinsurance Miscellaneous financial loss insurance and proportional reinsurance Non-proportional health reinsurance Non-proportional casualty reinsurance Non-proportional marine, aviation and transport reinsurance Non-proportional property reinsurance

Linear formula component for life insurance and reinsurance obligations

MCRL Result

C0040 R0200 10,421

R0170

	TP calculated as a whole	
	C0050	C0060
R0210		
R0220		
R0230		
R0240	496	
R0250		

Net (of

reinsurance/SPV)

Net (of

surance/SPV

Obligations with profit participation - Guaranteed benefits Obligations with profit participation - Future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations

Overall MCR calculation

Linear MCR SCR MCR cap MCR floor Combined MCR Absolute floor of the MCR

Minimum Capital Requirement

	C0070	
R0300	3,330	
R0310	4,817	
R0320	2,168	
R0330	1,204	
R0340	2,168	
R0350	3,445	
	C0070	
R0400	3,445	

F.2 Glossary of Abbreviations and Definitions A glossary explaining the key terms used in this report is available on www.aviva.com/glossary.	

F.3 Directors' Statement

We acknowledge our responsibility for preparing the Solvency and Financial Condition Report of Gresham Insurance Company Limited 31 December 2022 in all material respects in accordance with the PRA Rules and the Solvency II Regulations.

The Board is satisfied that to the best of its knowledge and belief:

- (a) throughout the financial year to 31 December 2022, the Company has complied in all material respects with the requirements of the PRA rules and Solvency II Regulations as applicable to the Company; and
- (b) it is reasonable to believe that in respect of the period from 31 December 2022 to the date of the publication of the SFCR, the Company has continued so to comply and that it will continue so to comply for the remainder of the financial year to 31 December 2023.

J C Holliday

Director

6 April 2023

F.4 External Audit The PRA issued Policy Statement PS25/18 in October 2018 which removes the external audit requirement for the SFCR of certain s Solvency II firms. As the Company meets the criteria of a small Solvency II firm there is no requirement for this SFCR to be aud Consequently, all qualitative and quantitative disclosure in this document is unaudited.	mall ited.